[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 826
1. Doghman M, Cazareth J, Douguet D, Madoux F, Hodder P, Lalli E: Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. J Clin Endocrinol Metab; 2009 Jun;94(6):2178-83
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists.
  • CONTEXT: Transcription factor steroidogenic factor-1 (SF-1) plays a pivotal role in the control of adrenocortical cell steroidogenesis and proliferation.
  • SF-1 amplification and overexpression are found in most cases of childhood adrenocortical tumors (ACTs).
  • OBJECTIVE: Our objective was to investigate the effect of SF-1 inverse agonists of the alkyloxyphenol and isoquinolinone classes on the proliferation of human adrenocortical cell lines expressing SF-1 (H295R), in conditions of basal and increased SF-1 expression, or negative for SF-1 expression (SW-13).
  • RESULTS: SF-1 inhibitors of the alkyloxyphenol class displayed a dose-dependent inhibitory effect on both SF-1-positive and -negative ACT cells, whereas SF-1 inverse agonists of the isoquinolinone class selectively inhibited cell proliferation elicited by SF-1 overexpression.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2002 Feb;143(2):607-14 [11796516.001]
  • [Cites] Dev Dyn. 1995 Sep;204(1):22-9 [8563022.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] J Natl Cancer Inst. 1973 Aug;51(2):691-7 [4765382.001]
  • [Cites] Cell. 1994 May 20;77(4):481-90 [8187173.001]
  • [Cites] Mol Endocrinol. 1995 Apr;9(4):478-86 [7659091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10939-43 [7479914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):4895-900 [9144161.001]
  • [Cites] Mol Endocrinol. 1998 Feb;12(2):290-301 [9482669.001]
  • [Cites] Endocrinology. 1998 Jun;139(6):3026-9 [9607816.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):615-9 [15546904.001]
  • [Cites] Cell. 2005 Feb 11;120(3):343-55 [15707893.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):491-502 [15721253.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7505-10 [15897460.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):3886-96 [15886257.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1040-3 [16574405.001]
  • [Cites] Endocrinology. 2006 Nov;147(11):5249-58 [16887917.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):3253-60 [17566092.001]
  • [Cites] Mol Endocrinol. 2007 Dec;21(12):2968-87 [17761949.001]
  • [Cites] Mol Pharmacol. 2008 Mar;73(3):900-8 [18055761.001]
  • [Cites] Bioorg Med Chem Lett. 2008 Apr 15;18(8):2628-32 [18374567.001]
  • [Cites] Mol Pharmacol. 2008 Jun;73(6):1776-84 [18334597.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):3222-5 [18544621.001]
  • [Cites] Expert Opin Emerg Drugs. 2008 Sep;13(3):497-509 [18764725.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3524-31 [18611974.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):204-12 [18854392.001]
  • [Cites] Endocrinology. 2009 Mar;150(3):1303-9 [18974272.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • (PMID = 19318454.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / U54 MH084512; United States / NIMH NIH HHS / MH / 1U54MH084512
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(heptyloxy)phenol; 0 / NR5A1 protein, human; 0 / Phenols; 0 / Quinolones; 0 / Steroidogenic Factor 1; 0 / Steroids
  • [Other-IDs] NLM/ PMC2690427
  •  go-up   go-down


2. Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E: Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol; 2010 Jun;162(6):1147-53
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?
  • CONTEXT: Peritoneal carcinomatosis (PC) is a rare site of distant metastases in patients with adrenocortical cancer (ACC).
  • One preliminary study suggests an increased risk of PC after laparoscopic adrenalectomy (LA) for ACC.
  • Patients had stage I disease in 2 cases, stage II disease in 32 cases, stage III disease in 7 cases, stage IV disease in 21 cases, and unknown stage disease in 2 cases.
  • It was present at initial diagnosis in three cases and occurred during follow-up in 15 cases.
  • The only risk factor of PC occurring during follow-up was the surgical approach with a 4-year rate of PC of 67% (95% confidence interval (CI), 30-90%) for LA and 27% (95% CI, 15-44%) for open adrenalectomy (P=0.016).
  • CONCLUSION: We found an increased risk of PC after LA for ACC.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348273.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Veytsman I, Nieman L, Fojo T: Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol; 2009 Sep 20;27(27):4619-29
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
  • Adrenal cortical carcinoma (ACC) is a rare malignancy in which patients have poor overall 5-year survival.
  • In many patients with ACC, advanced disease at presentation precludes surgery or is followed by local relapse or distant metastatic disease that cannot be managed surgically.
  • Physicians who treat patients with ACC and severe hypercortisolism should recognize that uncontrolled hormone production is a malignant disease, which has severe consequences that require aggressive management.
  • In the absence of randomized, controlled trials, adjuvant use of mitotane remains controversial, although the authors of a recent case-control study argue for its use.
  • Recommendations are provided to help manage patients with this difficult disease and to improve the quality of their lives.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / physiopathology. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / physiopathology. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Adrenocortical Hyperfunction / drug therapy. Adrenocortical Hyperfunction / etiology. Female. Humans. Male

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1987 Sep 12;2(8559):637-8 [2887934.001]
  • [Cites] N Engl J Med. 1987 Sep 24;317(13):812-8 [3306384.001]
  • [Cites] Antimicrob Agents Chemother. 1987 Dec;31(12):1874-8 [3326525.001]
  • [Cites] Eur J Clin Pharmacol. 1987;33(4):391-6 [3443145.001]
  • [Cites] Klin Wochenschr. 1988 Apr 15;66(8):361-4 [3392892.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):765-9 [2743269.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Jul;31(1):51-7 [2574647.001]
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] J Clin Endocrinol Metab. 1990 May;70(5):1426-30 [2159485.001]
  • [Cites] J Urol. 1990 Nov;144(5):1100-3; discussion 1103-4 [2231879.001]
  • [Cites] Am J Clin Oncol. 1991 Apr;14(2):170-4 [1709336.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):2997-3000 [2044046.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Aug;35(2):169-78 [1657460.001]
  • [Cites] Surgery. 1991 Dec;110(6):1006-13 [1745969.001]
  • [Cites] Radiology. 1992 Nov;185(2):345-51 [1410337.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):161-5 [8418229.001]
  • [Cites] Q J Med. 1992 Sep;84(305):671-9 [1480741.001]
  • [Cites] Cancer. 1993 May 15;71(10):3119-23 [8490842.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):683-8 [7512126.001]
  • [Cites] Br J Cancer. 1994 May;69(5):947-51 [8180029.001]
  • [Cites] N Engl J Med. 1994 Oct 13;331(15):968-73 [8084355.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Sep;23(3):571-84 [7805655.001]
  • [Cites] AJR Am J Roentgenol. 1996 Mar;166(3):531-6 [8623622.001]
  • [Cites] Radiology. 1996 Sep;200(3):749-52 [8756926.001]
  • [Cites] Cancer Treat Res. 1997;89:217-37 [9204195.001]
  • [Cites] Oncology. 1997 Nov-Dec;54(6):490-6 [9394846.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):546-9 [9716042.001]
  • [Cites] Endocr Rev. 1998 Oct;19(5):647-72 [9793762.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2194-200 [9827725.001]
  • [Cites] Radiology. 1999 Jul;212(1):35-41 [10405717.001]
  • [Cites] Endocrinology. 1958 Mar;62(3):334-9 [13512246.001]
  • [Cites] J Lab Clin Med. 1961 Aug;58:296-304 [13773354.001]
  • [Cites] Am J Med. 1955 Dec;19(6):966-75 [13275491.001]
  • [Cites] J Clin Endocrinol Metab. 1959 Aug;19:875-94 [14416789.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):284-9 [15671557.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):149-59 [15788646.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Apr;6(4):386-94 [15898346.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2650-5 [16670169.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4501-4 [16895957.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Ann Pharmacother. 2007 Feb;41(2):350-3 [17213295.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1256-7; author reply 1259 [17881760.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1257-8; author reply 1259 [17891838.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1526-40 [18334580.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81 [18552288.001]
  • [Cites] Cancer Chemother Pharmacol. 1981;7(1):51-4 [7340988.001]
  • [Cites] Ann Intern Med. 1982 Sep;97(3):370-2 [6287893.001]
  • [Cites] Arch Surg. 1982 Sep;117(9):1142-6 [7115060.001]
  • [Cites] Arch Intern Med. 1982 Nov;142(12):2137-40 [6291475.001]
  • [Cites] J Clin Invest. 1983 Jul;72(1):404-8 [6135709.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Oct;57(4):732-6 [6309882.001]
  • [Cites] Surgery. 1983 Dec;94(6):926-31 [6648806.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):36-42 [16357562.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):920-5 [16368753.001]
  • [Cites] J Formos Med Assoc. 2006 Apr;105(4):340-5 [16618615.001]
  • [Cites] World J Surg. 2006 May;30(5):872-8 [16680602.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2459-65 [16615097.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2665-71 [16621901.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1159-65 [10699907.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2234-8 [10852456.001]
  • [Cites] Braz J Med Biol Res. 2000 Oct;33(10):1197-200 [11004720.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] World J Surg. 2001 Jun;25(6):735-8 [11376408.001]
  • [Cites] Med Klin (Munich). 2001 Jul 15;96(7):371-7 [11494911.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4104-8 [11549633.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6762-7 [11559548.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1385-92 [11745214.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Pituitary. 2002;5(2):77-82 [12675504.001]
  • [Cites] Clin Nucl Med. 2003 Jun;28(6):494-7 [12917534.001]
  • [Cites] Med Clin North Am. 2004 Mar;88(2):443-66 [15049587.001]
  • [Cites] Am J Med. 1966 Oct;41(4):572-80 [5923598.001]
  • [Cites] Am J Med. 1966 Oct;41(4):581-92 [5923599.001]
  • [Cites] Med Clin North Am. 1972 Jul;56(4):999-1012 [5034421.001]
  • [Cites] JAMA. 1973 Mar 5;223(10):1109-12 [4739370.001]
  • [Cites] J Steroid Biochem. 1973 Nov;4(6):585-91 [4789318.001]
  • [Cites] J Clin Endocrinol Metab. 1976 Apr;42(4):687-95 [1262443.001]
  • [Cites] Acta Endocrinol (Copenh). 1976 Jun;82(2):330-41 [179256.001]
  • [Cites] Cancer. 1979 Jul;44(1):239-44 [455249.001]
  • [Cites] Ann Intern Med. 1980 Dec;93(6):921-3 [6255850.001]
  • [Cites] Cancer. 1981 May 1;47(9):2153-61 [7226109.001]
  • [Cites] Clin Endocrinol (Oxf). 1981 Jan;14(1):31-9 [7226574.001]
  • [Cites] Antimicrob Agents Chemother. 1981 Jun;19(6):1073-4 [6267997.001]
  • [Cites] Clin Endocrinol (Oxf). 1981 May;14(5):485-92 [6273022.001]
  • [Cites] Ann Intern Med. 1982 Apr;96(4):440-3 [6279005.001]
  • [Cites] Antimicrob Agents Chemother. 1983 Oct;24(4):478-85 [6316842.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53 [6537915.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):503-13 [6319220.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] N Engl J Med. 1984 May 31;310(22):1415-21 [6325910.001]
  • [Cites] Klin Wochenschr. 1984 May 15;62(10):470-7 [6379276.001]
  • [Cites] Int Adv Surg Oncol. 1984;7:329-53 [6088397.001]
  • [Cites] Anaesthesia. 1984 Oct;39(10):973-81 [6496912.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Mar;22(3):281-6 [2983910.001]
  • [Cites] Klin Wochenschr. 1985 Jul 1;63(13):607-12 [2993735.001]
  • [Cites] Acta Endocrinol (Copenh). 1985 Aug;109(4):451-7 [3898689.001]
  • [Cites] Eur J Clin Pharmacol. 1985;29(2):241-5 [2934265.001]
  • [Cites] JAMA. 1986 Mar 7;255(9):1167-9 [3003415.001]
  • [Cites] South Med J. 1986 Mar;79(3):387-8 [3952554.001]
  • [Cites] J Steroid Biochem. 1986 Jan;24(1):321-3 [3702414.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Oct 18;293(6553):993-4 [3094767.001]
  • [Cites] J Pharmacol Exp Ther. 1987 Jan;240(1):259-64 [3027305.001]
  • [Cites] Lancet. 1987 Mar 7;1(8532):573 [2881126.001]
  • [CommentIn] J Clin Oncol. 2010 Aug 10;28(23):e401-2; author reply e403 [20567001.001]
  • (PMID = 19667279.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIE HD008832-03
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  • [Number-of-references] 120
  • [Other-IDs] NLM/ PMC2754909
  •  go-up   go-down


Advertisement
4. Russell-Swetek A, West AN, Mintern JE, Jenkins J, Rodriguez-Galindo C, Ribeiro R, Zambetti GP: Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J Med Genet; 2008 Sep;45(9):603-6
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma.
  • Paediatric choroid plexus carcinomas (CPC) and adrenocortical carcinomas (ACC) are exceedingly rare tumours, each occurring at an annual rate of 0.3 cases per million children or less.
  • We report here a young boy without a family history of cancer who presented with CPC and subsequently ACC.
  • Genetic testing revealed a novel de novo germline TP53 mutation (E285V).

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854256 for PMID:18762572 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1998 Nov;57(11):1061-9 [9825943.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):265-73 [15747338.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5056-62 [16707427.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):370-3 [17671971.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6C):5563-5 [10697617.001]
  • [Cites] Am J Hum Genet. 1999 Oct;65(4):995-1006 [10486318.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):15-30 [11602342.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jan;126(1):70-2 [11800650.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Genes Dev. 1992 Jul;6(7):1143-52 [1628822.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 [9215267.001]
  • (PMID = 18762572.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA63230; United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA23944; United States / NCI NIH HHS / CA / R01 CA063230
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS404658; NLM/ PMC3487594
  •  go-up   go-down


5. Shen WT, Sturgeon C, Duh QY: From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol; 2005 Mar 1;89(3):186-92
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors.
  • In this article we review the management of benign and malignant adrenal tumors, with an emphasis on oncologic concerns.
  • Concise, logical guidelines for the diagnosis and operative treatment of incidentalomas, aldosteronomas, adrenal Cushing syndrome, virilizing and feminizing adrenal tumors, isolated adrenal metastases, and adrenocortical carcinoma are provided.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Laparoscopy
  • [MeSH-minor] Adrenal Gland Neoplasms / radiography. Adrenal Gland Neoplasms / secondary. Adrenocorticotropic Hormone / blood. Aldosterone / blood. Cushing Syndrome / diagnosis. Humans. Incidental Findings. Magnetic Resonance Imaging. Radiography, Abdominal. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15719374.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone; 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 32
  •  go-up   go-down


6. Ochi T, Tanji N, Shimamoto K, Ikeda T, Toshino A, Yokoyama M: Application of cardiopulmonary bypass for resection of renal cell carcinoma and adrenocortical carcinoma extending into the right atrium. Int J Urol; 2006 Mar;13(3):202-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of cardiopulmonary bypass for resection of renal cell carcinoma and adrenocortical carcinoma extending into the right atrium.
  • AIM: The application of cardiopulmonary bypass to atrial involvement represents an important advance that has improved the safety and technical efficacy of a difficult surgical undertaking.
  • Tumors originated in the right kidney in four patients, and in left adrenal gland in one patient.
  • Of the five patients, three died of metastatic diseases, one died of liver dysfunction and one remains disease free as of 18 months postoperatively.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Carcinoma, Renal Cell / surgery. Cardiac Surgical Procedures / methods. Cardiopulmonary Bypass / methods. Heart Neoplasms / surgery. Kidney Neoplasms / surgery


7. Di Carlo I, Toro A, Sparatore F, Cordio S: Liver resection for hepatic metastases from adrenocortical carcinoma. HPB (Oxford); 2006;8(2):106-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for hepatic metastases from adrenocortical carcinoma.
  • Liver metastases from adrenocortical carcinoma are very rare and no clear indications for surgery exist.
  • All the patients submitted to hepatic resection for liver metastases from adrenal carcinoma reported in the literature (PubMed source) from 1978 to 2005 were considered for the present study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Oct;85(10):1423-7 [9782030.001]
  • [Cites] Chirurg. 1999 Apr;70(4):439-46 [10354843.001]
  • [Cites] Liver Transpl. 2000 Jan;6(1):97-101 [10648585.001]
  • [Cites] Dig Surg. 1999;16(6):459-67 [10805544.001]
  • [Cites] Langenbecks Arch Surg. 2000 Oct;385(6):393-7 [11127523.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1532-6 [11775186.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):535-7 [11995490.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):343-5 [15086154.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):269-76 [15650637.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Ann Surg. 1988 Oct;208(4):421-34 [3178330.001]
  • [Cites] Surg Gynecol Obstet. 1987 Sep;165(3):239-46 [3629438.001]
  • [Cites] Am J Surg. 1978 Mar;135(3):389-94 [626320.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Oncology. 1997 Nov-Dec;54(6):490-6 [9394846.001]
  • (PMID = 18333256.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2131421
  •  go-up   go-down


8. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD: Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol; 2010 Mar;65(4):765-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
  • PURPOSE: Insulin-like growth factor 1 receptor signaling through upregulation of the stimulatory ligand IGF-II has been implicated in the pathogenesis of adrenocortical carcinoma.
  • As there is a paucity of effective therapies, this dose expansion cohort of a phase 1 study was undertaken to determine the safety, tolerability, pharmacokinetics, and effects on endocrine markers of figitumumab in patients with adrenocortical carcinoma.
  • METHODS: Figitumumab was administered on day 1 of each 21-day cycle at the maximal feasible dose (20 mg/kg) to a cohort of patients with metastatic, refractory adrenocortical carcinoma.
  • RESULTS: Fourteen patients with adrenocortical carcinoma received 50 cycles of figitumumab at the 20 mg/kg.
  • Pharmacokinetics of figitumumab was comparable to patients with solid tumors other than adrenocortical carcinoma.
  • Eight of 14 patients (57%) had stable disease.
  • CONCLUSIONS: The side effect profile and pharmacokinetics of figitumumab were similar in patients with adrenocortical carcinoma in comparison to patients with other solid tumors.
  • The majority of patients receiving protocol therapy with single agent figitumumab experienced stability of disease, warranting further evaluation.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antibodies, Monoclonal / pharmacokinetics. Receptor, IGF Type 1 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Neurol Res. 2005 Jan;27(1):27-35 [15829155.001]
  • [Cites] Neoplasia. 2002 Sep-Oct;4(5):400-8 [12192598.001]
  • [Cites] Endocrinology. 2002 Sep;143(9):3259-67 [12193537.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3796-802 [12473592.001]
  • [Cites] Med Sci Monit. 2002 Dec;8(12):BR521-6 [12503030.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):627-35 [12566306.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3825-35 [14666684.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):505-18 [15229476.001]
  • [Cites] Lancet. 1988 Nov 19;2(8621):1170-2 [2903379.001]
  • [Cites] J Biol Chem. 1993 Nov 5;268(31):23435-40 [7693688.001]
  • [Cites] Eur J Cancer. 1993;29A(16):2256-64 [8110496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111 [16113104.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4609-18 [16037379.001]
  • [Cites] Surgery. 2005 Dec;138(6):1087-94 [16360395.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):14-21 [16234301.001]
  • [Cites] Tohoku J Exp Med. 2006 Jul;209(3):217-28 [16778368.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):1-22 [16844299.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2557-66 [16988945.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):600-8 [17234769.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1155-62 [17283150.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5834-40 [17908976.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3196-203 [18474873.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):204-12 [18854392.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2516-22 [19380445.001]
  • [Cites] J Biol Chem. 1994 Jun 10;269(23):16034-40 [8206901.001]
  • [Cites] N Engl J Med. 1997 Feb 27;336(9):633-40 [9032050.001]
  • [Cites] Eur J Endocrinol. 1997 Mar;136(3):296-303 [9100555.001]
  • [Cites] J Clin Invest. 1997 May 15;99(10):2538-44 [9153298.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] Mol Cell. 1998 Nov;2(5):559-69 [9844629.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):2063-73 [15756033.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):203-20 [15650828.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • (PMID = 19649631.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / K12 CA090628-05
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulins, Intravenous; 0 / Insulin; 9002-72-6 / Growth Hormone; EC 2.7.10.1 / Receptor, IGF Type 1; VE267FC2UB / figitumumab
  • [Other-IDs] NLM/ NIHMS190253; NLM/ PMC2875253
  •  go-up   go-down


9. Doghman M, Cazareth J, Lalli E: The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab; 2008 Aug;93(8):3222-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells.
  • CONTEXT: Mutations of the beta-catenin (CTNNB1) gene are frequently found in adrenocortical tumors.
  • OBJECTIVE: The objective of the study was to investigate the effect of the small-molecule inhibitor of the T cell factor (Tcf)/beta-catenin complex PKF115-584 on beta-catenin-dependent transcription and proliferation of H295R adrenocortical tumor cells, which harbor mutations in CTNNB1 as well as the TP53 tumor suppressor gene.
  • PKF115-584 dose-dependently inhibited beta-catenin-dependent transcription and H295R proliferation, even in the presence of increased steroidogenic factor-1 levels, which augment proliferation in this cell line.
  • The drug had no effect on HeLa cells, a cell line in which the beta-catenin pathway is not activated.
  • CONCLUSIONS: Inhibitors of the Tcf/beta-catenin complex may prove useful in the treatment of adrenocortical tumors in which multiple genetic alterations have accumulated.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. TCF Transcription Factors / antagonists & inhibitors. beta Catenin / antagonists & inhibitors
  • [MeSH-minor] Cell Proliferation / drug effects. Genes, p53. Humans. Mutation. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544621.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TCF Transcription Factors; 0 / beta Catenin
  •  go-up   go-down


10. Lichtenauer UD, Shapiro I, Geiger K, Quinkler M, Fassnacht M, Nitschke R, Rückauer KD, Beuschlein F: Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology; 2008 Mar;149(3):1314-22
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R.
  • Recent evidence suggests the existence of a stem cell-like subpopulation of cells in hematological and solid tumor entities, which determine the malignant phenotype of a given tumor through their proliferative potential and chemotherapy resistance.
  • A recently used technique for the isolation of this cell population is through exclusion of the vital dye Hoechst 33342, which defines the so-called side population (SP).
  • Herein we demonstrate the presence of SP cells in a variety of adrenal specimens, including primary cultures of human adrenocortical tumors and normal adrenal glands as well as established human and murine adrenocortical cancer cell lines by fluorescence-activated cell sorter analysis and confocal microscopy.
  • On a functional level, SP cells from the human adrenocortical tumor cell line NCI h295R revealed an expression pattern consistent with a less differentiated phenotype, including lower expression of steroidogenic enzymes such as steroid acute regulatory protein (StAR) and side-chain cleavage enzyme (P450scc) in comparison with non-SP cells.
  • Furthermore, re-sorting and tracing experiments revealed the capacity for both cell types to give rise to the original SP- and non-SP-containing cell population.
  • Similarly to the baseline growth kinetics, no survival benefit was evident in SP cells after treatment with cytotoxic agents commonly used in adrenocortical carcinomas.
  • Taken together, these findings provide evidence that Hoechst dye exclusion, in contrast to what has been reported for other tumor entities, is not a major tumor stem cell defining marker in adrenocortical NCI h295R tumor cells.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Neoplastic Stem Cells / cytology
  • [MeSH-minor] Adrenal Glands / cytology. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Cycle / physiology. Cell Differentiation / physiology. Cell Line, Tumor. Cell Proliferation. Cholesterol Side-Chain Cleavage Enzyme / metabolism. Coloring Agents. Drug Resistance, Neoplasm / physiology. Humans. Phenotype. Phosphoproteins / metabolism. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063677.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Coloring Agents; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; EC 1.14.15.6 / Cholesterol Side-Chain Cleavage Enzyme
  •  go-up   go-down


11. Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, Sigal R, Baudin E, Schlumberger M: Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab; 2006 Mar;91(3):920-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography.
  • OBJECTIVE: Patients with adrenocortical cancer are submitted to multiple imaging procedures for diagnosis of recurrence and staging.
  • METHODS: Twenty-eight consecutive patients with adrenocortical cancer referred from November 2003 to December 2004 to the Institut Gustave Roussy were included.
  • The sensitivities for the detection of distinct lesions and the diagnosis of metastatic organs were 90 and 93% for PET/CT and 88 and 82% for TAP-CT, respectively.
  • CONCLUSIONS: We show that FDG-PET/CT is complementary to TAP-CT and of special interest in the diagnosis of local relapses.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiography. Adrenal Cortex Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368753.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Jaroenporn S, Furuta C, Nagaoka K, Watanabe G, Taya K: Comparative effects of prolactin versus ACTH, estradiol, progesterone, testosterone, and dihydrotestosterone on cortisol release and proliferation of the adrenocortical carcinoma cell line H295R. Endocrine; 2008 Apr;33(2):205-9
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative effects of prolactin versus ACTH, estradiol, progesterone, testosterone, and dihydrotestosterone on cortisol release and proliferation of the adrenocortical carcinoma cell line H295R.
  • In this study, using the H295R cell line as a model system, we investigated the role of prolactin (PRL) and steroid hormones in the growth regulation and cortisol release of adrenocortical cells.
  • Long-term (5 days) stimulation of H295R cells with E(2), P(4), and PRL was a trigger to increased cell proliferation, while T and DHT did not alter H295R cell proliferation.
  • Taken together, these results indicate that steroid hormones exert differential effects on adrenocortical function.
  • Additionally, the present study demonstrates that PRL had biphasic actions in regulating adrenocortical function.
  • PRL may form a novel regulatory system for steroid hormone secretion and cell proliferation in the adrenal cortex.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Cell Proliferation / drug effects. Gonadal Steroid Hormones / pharmacology. Hydrocortisone / metabolism. Prolactin / pharmacology
  • [MeSH-minor] Adrenocorticotropic Hormone / pharmacology. Cell Line, Tumor. Dihydrotestosterone / pharmacology. Dose-Response Relationship, Drug. Estradiol / pharmacology. Humans. Progesterone / pharmacology. Radioimmunoassay. Testosterone / pharmacology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18484195.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 08J2K08A3Y / Dihydrotestosterone; 3XMK78S47O / Testosterone; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


13. Weismann D, Briese J, Niemann J, Grüneberger M, Adam P, Hahner S, Johanssen S, Liu W, Ezzat S, Saeger W, Bamberger AM, Fassnacht M, Schulte HM, Asa SL, Allolio B, Bamberger CM: Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol; 2009 Jun;218(2):232-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma.
  • Gene array studies indicated that osteopontin (OPN) mRNA is highly expressed in adrenocortical carcinomas (ACCs).
  • OPN enhances invasiveness, proliferation, and metastasis formation, and is associated with poor survival in some malignant diseases.
  • In this study, we demonstrated OPN and integrin alphavbeta3 expression in normal adrenal glands and benign adenomas, with staining seen exclusively in adrenocortical cells as well as even stronger staining in ACC.
  • In conclusion, our in vitro data indicate that OPN and integrin alphavbeta3 may act as a functional complex facilitating the invasiveness of adrenocortical tumours.
  • This relationship remains of relevance to our understanding of carcinogenesis, but further studies are needed to address the physiological and pathological function of OPN in adrenal tissue.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Osteopontin / analysis
  • [MeSH-minor] Adenoma / chemistry. Adrenal Glands / chemistry. Blotting, Western / methods. Cell Line, Tumor. Gene Expression Profiling. Humans. Immunohistochemistry. Integrin alphaVbeta3 / analysis. Integrin alphaVbeta3 / genetics. Integrin alphaVbeta3 / metabolism. Kaplan-Meier Estimate. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Transfection / methods

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19326399.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 106441-73-0 / Osteopontin
  •  go-up   go-down


14. Shimony A, Bereza S, Shalev A, Gilutz H, Ilia R, Zahger D: Ventricular fibrillation as the presenting manifestation of adrenocortical carcinoma. Am Heart Hosp J; 2009;7(1):65-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ventricular fibrillation as the presenting manifestation of adrenocortical carcinoma.
  • We describe a case of a young adult in whom sudden cardiac death due to ventricular fibrillation was the presenting manifestation of an adrenocortical carcinoma.
  • Sudden death has not been previously described as a manifestation of this adrenal neoplasm.
  • Unexplained persistent hypokalemia after resuscitated sudden death (especially when combined with hypertension( should prompt investigation for an underlying secondary hypertension, particularly adrenal pathology.
  • Adrenocortical carcinoma should be considered in the differential diagnosis of unexplained sudden death associated with unexplained hypokalemia.
  • [MeSH-major] Adrenal Cortex Neoplasms / complications. Adrenocortical Carcinoma / complications. Ventricular Fibrillation / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19742438.001).
  • [ISSN] 1751-7168
  • [Journal-full-title] The American heart hospital journal
  • [ISO-abbreviation] Am Heart Hosp J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Müssig K, Wehrmann M, Horger M, Teichmann R, Maser-Gluth C, Häring HU, Overkamp D: Steroid profile in an adrenocortical carcinoma producing aldosterone. Exp Clin Endocrinol Diabetes; 2005 Apr;113(4):236-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid profile in an adrenocortical carcinoma producing aldosterone.
  • We report a rare case of primary aldosteronism due to an adrenocortical carcinoma.
  • A 61-year-old woman with a history of hypertension and hypokalemia was referred for evaluation of a 4.2 cm measuring adrenal mass without secondary signs of malignancy.
  • The patient underwent surgical resection of the adrenal mass; histology revealed an adrenocortical carcinoma.
  • Four months after adrenalectomy, the patient presented again with hypokalemic hypertension and was found to have metastatic disease.
  • Careful hormonal investigation should be obtained in patients with adrenal masses causing excessive aldosterone secretion.
  • In uncertain cases of primary aldosteronism, we would suggest to measure 18-hydroxycortisol levels, as excessive amounts may indicate adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / blood. Adrenal Cortex Neoplasms / secretion. Aldosterone / secretion
  • [MeSH-minor] Adrenal Cortex Hormones / blood. Female. Humans. Middle Aged. Posture. Supine Position. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891961.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 4964P6T9RB / Aldosterone
  •  go-up   go-down


16. Satter EK, Barnette DJ: Adrenocortical carcinoma with delayed cutaneous metastasis. J Cutan Pathol; 2008 Jul;35(7):677-80
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma with delayed cutaneous metastasis.
  • Adrenal cortical carcinoma (ACC) is an uncommon and aggressive malignancy.
  • Patients often have metastatic disease at initial presentation, with the most common sites being the liver, local lymph nodes, lungs, peritoneum and bone.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / secondary. Skin / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Lung / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Middle Aged. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201231.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


17. Cazejust J, De Baère T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M, Leboulleux S, Baudin E: Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol; 2010 Oct;21(10):1527-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma.
  • PURPOSE: To retrospectively evaluate the effectiveness, tolerance, and predictors of response to transcatheter arterial chemoembolization for treatment of liver metastases from adrenocortical carcinoma.
  • MATERIALS AND METHODS: Twenty-nine patients with progressive liver metastases from adrenocortical carcinoma were treated with transcatheter arterial chemoembolization.
  • RESULTS: Three months after transcatheter arterial chemoembolization, a liver morphologic response was observed in six of 29 patients (21%), stabilization in 18 (62%), and progression in five (17%).
  • According to per-lesion analysis (n = 103), a morphologic response was observed in 23 lesions (22%), stabilization in 67 (65%), and progression in 13 (13%).
  • CONCLUSIONS: Transcatheter arterial chemoembolization should be considered as part of the therapeutic arsenal to treat liver metastases from adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / secondary. Hemostatics / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20801688.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics
  •  go-up   go-down


18. Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Duh QY, Clark OH, Kebebew E: Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg; 2008 Sep;143(9):841-6; discussion 846
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling.
  • HYPOTHESIS: The gene expression profiles of benign and malignant adrenocortical tumors are different.
  • PATIENTS: Eighty-five patients with benign adrenocortical tumors (n = 74) and adrenocortical carcinoma (n = 11).
  • INTERVENTION: Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) in 89 adrenocortical tissue samples (11 malignant and 78 benign).
  • The criteria for differentially expressed genes between benign and malignant adrenocortical tumors were a false discovery rate of less than 5% and an adjusted P < .01.
  • Fifteen genes were downregulated and 22 were upregulated in adrenocortical carcinoma.
  • Of the 37 genes validated by RT-PCR, 22 were significantly differentially expressed between benign and malignant adrenocortical tumors (P < .05).
  • Five of these 22 genes had an AUC of 0.80 or greater (the AUC for IL13RA2 was 0.90; HTR2B, 0.87; CCNB2, 0.86; RARRES2, 0.86; and SLC16A9, 0.80), indicating high diagnostic accuracy for distinguishing benign from malignant adrenocortical tumors.
  • CONCLUSION: We identified 37 genes that are dysregulated in adrenocortical carcinoma, and several of the differentially expressed genes have excellent diagnostic accuracy for distinguishing benign from malignant adrenocortical tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Biomarkers, Tumor. Gene Expression Profiling. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adrenal Cortex. Adult. Aged. Area Under Curve. Chemokines / metabolism. Cyclin B / metabolism. Cyclin B2. Female. Humans. Intercellular Signaling Peptides and Proteins. Interleukin-13 Receptor alpha2 Subunit / metabolism. Male. Middle Aged. Monocarboxylic Acid Transporters / metabolism. Oligonucleotide Array Sequence Analysis. Pituitary ACTH Hypersecretion / etiology. ROC Curve. Receptor, Serotonin, 5-HT2B / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794420.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCNB2 protein, human; 0 / Chemokines; 0 / Cyclin B; 0 / Cyclin B2; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Monocarboxylic Acid Transporters; 0 / Receptor, Serotonin, 5-HT2B; 0 / chemerin protein, human
  •  go-up   go-down


19. Fujiwara M, Kamma H, Wu W, Yano Y, Homma S, Satoh H: Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R. Int J Oncol; 2006 Aug;29(2):445-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R.
  • It has been reported that clinical samples of adrenocortical carcinoma show a low incidence of telomerase positivity.
  • We characterized an adrenocortical carcinoma cell line, H295R, focusing on the telomere maintenance mechanism, and compared it with telomerase-positive 293 cells and HeLa cells.
  • In conclusion, the H295R adrenocortical carcinoma cell line is negative for telomerase and maintains its telomeres by the ALT mechanism.
  • [MeSH-major] Adrenal Cortex Neoplasms / ultrastructure. Carcinoma / ultrastructure. Telomere / ultrastructure
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / metabolism. HeLa Cells. Humans. In Situ Hybridization, Fluorescence. Neoplasms / metabolism. Oligonucleotides / chemistry. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Telomerase / metabolism

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820888.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Oligonucleotides; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


20. Arvanitis LD, Pitelka LA, Gattuso P: Adrenocortical carcinoma presenting with a peritoneal effusion. Diagn Cytopathol; 2010 Jul;38(7):514-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma presenting with a peritoneal effusion.
  • In this report, we describe the fine-needle aspiration findings of a case of adrenocortical carcinoma (ACC) that spread to the peritoneal cavity in an 80-year-old female.
  • Although ACC is the most common malignant neoplasm of the adrenal gland, its metastatic spread to the peritoneal cavity is exceptionally unusual.
  • [MeSH-major] Adrenocortical Carcinoma / complications. Adrenocortical Carcinoma / pathology. Ascitic Fluid / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19941369.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Nakamura M, Miki Y, Akahira J, Morimoto R, Satoh F, Ishidoya S, Arai Y, Suzuki T, Hayashi Y, Sasano H: An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocr Pathol; 2009;20(1):17-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma.
  • Adrenocortical carcinoma (ACC) is a rare neoplasm but some of the cases are highly malignant.
  • Target-specific therapies have been developed in a number of human malignancies and resulted in therapeutic benefits in some cancer patients.
  • Therefore, we evaluated expression of potential surrogate markers using immunohistochemistry in archival materials of adrenocortical carcinoma in order to explore the potential application of target specific therapies in ACC in this study.
  • We immunolocalized ten established or potential surrogate markers of target-specific therapies, located in the Ras/extracellular signal-regulated kinase and phosphatidylinositol-3 kinase/Akt pathways, in 41 ACC cases, 54 adrenocortical adenoma (ACA) cases, and five nonpathological adrenal glands and correlated the findings with clinicopathological factors of the patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers, Tumor / analysis. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Adolescent. Adrenocortical Adenoma. Adult. Aged. Child. Child, Preschool. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184558.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


22. Fareau GG, Lopez A, Stava C, Vassilopoulou-Sellin R: Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anticancer Drugs; 2008 Jul;19(6):637-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies.
  • The objective of this study was to evaluate and compare the efficacies of conventional first-line chemotherapies for adrenocortical carcinoma.
  • We identified 224 patients with a diagnosis of adrenocortical carcinoma, 57 of whom met the inclusion criteria for further study.
  • Our analysis revealed no clear advantage for any single agent or combination over any of the other conventional frontline chemotherapeutic choices for adrenocortical carcinoma.
  • Novel agents are thus sorely needed in the treatment of this aggressive cancer.
  • [MeSH-major] Adrenocortical Carcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Disease Progression. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitotane / administration & dosage. Regression Analysis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525324.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP, Kunter G, Rodriguez-Galindo C, Wallis JW, Hurwitz CA, Schteingart DE: Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab; 2006 Jul;91(7):2665-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.
  • CONTEXT: Adrenocortical carcinomas are uncommon, and their evaluation by [(18)F]fluorodeoxyglucose positron emission tomography (FDG PET) has not been well evaluated.
  • OBJECTIVE: The purpose of this study was to examine the potential utility of FDG PET in the detection of recurrent or metastatic adrenocortical carcinoma.
  • DESIGN: In patients with known adrenocortical carcinoma who underwent FDG-PET imaging for suspected recurrence or metastasis, FDG activity was compared with other imaging findings, clinical features, and the presence or absence of disease as confirmed by resection, biopsy, or clinical follow-up.
  • One patient with no abnormal FDG activity had a morphological abnormality subsequently proven to be a postoperative scar.
  • CONCLUSIONS: Most adrenocortical carcinomas accumulate and retain FDG and thus can be visualized by PET.
  • [MeSH-major] Adrenal Cortex Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621901.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R25 CA23944; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA 54216; United States / NCRR NIH HHS / RR / M01-RR00042
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. Rodgers SE, Evans DB, Lee JE, Perrier ND: Adrenocortical carcinoma. Surg Oncol Clin N Am; 2006 Jul;15(3):535-53
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma.
  • ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with the improvement in patient survival.
  • Even with appropriated diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies.
  • Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882496.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IGF2 protein, human; 0 / Proteins; 67763-97-7 / Insulin-Like Growth Factor II; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 85
  •  go-up   go-down


25. Suh I, Weng J, Fernandez-Ranvier G, Shen WT, Duh QY, Clark OH, Kebebew E: Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells. Arch Surg; 2010 Mar;145(3):226-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells.
  • HYPOTHESES: Decitabine recovers expression of silenced genes on chromosome 11q13 and has antineoplastic effects in adrenocortical carcinoma (ACC) cells.
  • Cells were evaluated at 24-hour intervals for the effects of decitabine on ACC cell proliferation, cortisol secretion, and cell invasion.
  • Study Specimen Human ACC cell line.
  • MAIN OUTCOME MEASURES: Adrenocortical carcinoma cell proliferation, cortisol secretion, and cell invasion were measured using immunometric assays.
  • RESULTS: Decitabine inhibited ACC cell proliferation by 39% to 47% at 5 days after treatment compared with control specimens (P < .001).
  • Decitabine decreased cortisol secretion by 56% to 58% at 5 days after treatment (P = .02) and inhibited cell invasion by 64% at 24 hours after treatment (P = .03).
  • CONCLUSIONS: Decitabine exhibits antitumoral properties in ACC cells at clinically achievable doses and may be an effective adjuvant therapy in patients with advanced disease.
  • Decitabine recovers expression of silenced genes on 11q13, which suggests a possible role of epigenetic gene silencing in adrenocortical carcinogenesis.
  • [MeSH-major] Adrenocortical Carcinoma / pathology. Antimetabolites, Antineoplastic / pharmacology. Azacitidine / analogs & derivatives

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):441-8 [10634422.001]
  • [Cites] Exp Cell Res. 1990 Mar;187(1):4-10 [2298260.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1170-6 [11889182.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):636-43 [12079511.001]
  • [Cites] Curr Opin Oncol. 2004 Jan;16(1):13-8 [14685087.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):994-1002 [14871978.001]
  • [Cites] Neurology. 2004 May 25;62(10):1899-901 [15159508.001]
  • [Cites] JAMA. 1973 Mar 5;223(10):1109-12 [4739370.001]
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Cell Growth Differ. 1992 Aug;3(8):515-21 [1356417.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):161-5 [8418229.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):684-9 [9012845.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8(4):358-68 [9180389.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):730-5 [10022445.001]
  • [Cites] J Mol Endocrinol. 2004 Dec;33(3):651-62 [15591025.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):632-40 [15695408.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1740-6 [16275995.001]
  • [Cites] Ann Hematol. 2005 Dec;84 Suppl 1:3-8 [16220311.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11 [16341240.001]
  • [Cites] J Endocrinol. 2006 Feb;188(2):305-10 [16461556.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] FEBS J. 2006 Jun;273(12):2607-17 [16817890.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3771-9 [16801630.001]
  • [Cites] Exp Cell Res. 2006 Sep 10;312(15):2806-15 [16781710.001]
  • [Cites] Surgery. 2006 Dec;140(6):914-20; discussion 919-20 [17188138.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1634-7 [17363514.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Aug;177(1):6-15 [17693185.001]
  • [Cites] Hear Res. 2008 Feb;236(1-2):52-60 [18207679.001]
  • [Cites] Neurosci Lett. 2008 Mar 15;433(3):219-24 [18262354.001]
  • [Cites] World J Surg. 2008 May;32(5):873-81 [18324346.001]
  • [Cites] Oncologist. 2008 May;13(5):548-61 [18515740.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3730-2 [18842984.001]
  • [Cites] Curr Probl Cancer. 2008 Sep-Oct;32(5):187-235 [18926282.001]
  • [Cites] Cancer Sci. 2008 Oct;99(10):1950-9 [19016754.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3130-6 [18973179.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 19;1574(2):164-74 [11955626.001]
  • [Cites] Endocr Res. 2000 Nov;26(4):921-30 [11196471.001]
  • (PMID = 20231622.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA BC011275-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS408412; NLM/ PMC3478887
  •  go-up   go-down


26. Lu CY, Yen TH, Hsieh ML, Chen Y: Spontaneous rupture of adrenocortical carcinoma: a coincidence or a tendency? Clin Nephrol; 2009 Aug;72(2):147-50
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous rupture of adrenocortical carcinoma: a coincidence or a tendency?
  • We report a rare case of adrenocortical carcinoma spontaneously rupturing.
  • To our knowledge, this is the sixth reported case in literature that is not related to any preceding traumatic incidents or predisposing disease.
  • Further study is warranted to validate our finding, but we suggest that if an adrenal tumor suspicious of malignant presentation is found incidentally, the size of tumor may warrant a more aggressive approach for prevention of tumor rupture and decrease in patient morbidity and mortality.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adrenalectomy / methods. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Rupture, Spontaneous. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640373.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Shaikh AH, Khalid SE, Junejo NN: Adrenocortical carcinoma with endocrine syndromes. J Coll Physicians Surg Pak; 2007 Nov;17(11):694-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma with endocrine syndromes.
  • Adrenocortical carcinoma is a rare disease.
  • She was found to have a large adrenocortical carcinoma with associated Cushing's and virilization syndromes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070581.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


28. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med; 2007 Jun 7;356(23):2372-80
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant mitotane treatment for adrenocortical carcinoma.
  • BACKGROUND: Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of recurrence after radical resection.
  • METHODS: We performed a retrospective analysis involving 177 patients with adrenocortical cancer who had undergone radical surgery at 8 centers in Italy and 47 centers in Germany between 1985 and 2005.
  • RESULTS: Baseline features in the mitotane group and the control group from Italy were similar; the German patients were significantly older (P=0.03) and had more stage I or II adrenocortical carcinomas (P=0.02) than did patients in the mitotane group.
  • CONCLUSIONS: Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use


29. Johanssen S, Fassnacht M, Brix D, Koschker AC, Hahner S, Riedmiller H, Allolio B: [Adrenocortical carcinoma. Diagnostic work-up and treatment]. Urologe A; 2008 Feb;47(2):172-81
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenocortical carcinoma. Diagnostic work-up and treatment].
  • Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis.
  • CT and MRI are equally sensitive and specific imaging tools for adrenal tumours.
  • Even after R0 resection, recurrence of the disease is frequent and regular follow-up for a minimum of 5 years is required.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / therapy. Adrenalectomy / methods. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / therapy. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030443.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  • [Number-of-references] 28
  •  go-up   go-down


30. Cheng MF, Wu YW, Tzen KY, Yen RF: F-18 FDG PET/CT illustrating tumor invasion in the IVC from adrenocortical carcinoma. Clin Nucl Med; 2007 Nov;32(11):891-2
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET/CT illustrating tumor invasion in the IVC from adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Fluorodeoxyglucose F18. Positron-Emission Tomography. Tomography, X-Ray Computed. Vena Cava, Inferior / pathology. Vena Cava, Inferior / radionuclide imaging

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075433.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


31. Heath V: Cancer: Second-line therapy for adrenocortical carcinoma proves beneficial. Nat Rev Endocrinol; 2010 Jul;6(7):355

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer: Second-line therapy for adrenocortical carcinoma proves beneficial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Endocr Relat Cancer. 2010 Jun;17(2):445-53 [20410174.001]
  • (PMID = 20583342.001).
  • [ISSN] 1759-5037
  • [Journal-full-title] Nature reviews. Endocrinology
  • [ISO-abbreviation] Nat Rev Endocrinol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP: Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer; 2005 Mar;12(1):149-59
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course.
  • Aldosterone-producing adrenocortical carcinoma (APAC) is a rare cause of hypertension often diagnosed late because of paucity of information.
  • Metastases were present in 10% of all cases at initial diagnosis and in an additional 48% of cases at follow-up.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis. Aldosterone / blood

  • Genetic Alliance. consumer health - Conn's Syndrome.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Endocr Relat Cancer. 2006 Mar;13(1):271
  • (PMID = 15788646.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone
  • [Number-of-references] 74
  •  go-up   go-down


33. Tucci S Jr, Martins AC, Suaid HJ, Cologna AJ, Reis RB: The impact of tumor stage on prognosis in children with adrenocortical carcinoma. J Urol; 2005 Dec;174(6):2338-42, discussion 2342
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of tumor stage on prognosis in children with adrenocortical carcinoma.
  • PURPOSE: We evaluated treatment outcomes in children with adrenocortical carcinoma.
  • Children with incomplete excision of the tumor and/or stage IV disease received adjuvant chemotherapy.
  • RESULTS: Ultrasonography, computerized tomography and magnetic resonance imaging exhibited specificity of 100% in the diagnosis of vascular invasion, and sensitivity of 50%, 66% and 100%, respectively.
  • Of 11 children with local recurrence only 2 were alive without disease at 96 and 204 months after reoperation with complete tumor excision.
  • Only 2 of 6 patients with vascular invasion were disease-free at 17 and 50 months.
  • A total of 10 children with stage IV disease treated with chemotherapy died within a median of 6 months.
  • CONCLUSIONS: Tumor stage was the most relevant prognostic factor for children with adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280838.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Fassnacht M: Recent advances in the diagnosis and treatment of adrenocortical carcinoma. Regul Pept; 2010 Sep 9;164(1):2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the diagnosis and treatment of adrenocortical carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26009320.001).
  • [ISSN] 0167-0115
  • [Journal-full-title] Regulatory peptides
  • [ISO-abbreviation] Regul. Pept.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


35. Ota K, Satoh H, Lin SY, Fujita J, Ohara G, Kurishima K, Hizawa N: Endobronchial metastasis from adrenocortical carcinoma. Intern Med; 2009;48(13):1161-4
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial metastasis from adrenocortical carcinoma.
  • We present herein a case of endobronchial metastasis from adrenocortical carcinoma.
  • In the English language literature, this is the first case with such rare metastasis from adrenocortical carcinoma diagnosed antemortem.
  • Although very rare, physicians should keep in mind the possibility of endobronchial metastasis in patients with a history of extrapulmonary malignancy including adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms. Bronchial Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571451.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


36. Dichtchekenian V, de Bragança Pereira CA, Kuperman H, Della Manna T, Damiani D, Ferreira Alves VA, Filho AL, Setian N: Adrenocortical carcinoma: prognostic indices based on clinical and immunohistochemical markers. J Pediatr Endocrinol Metab; 2005 Apr;18(4):347-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: prognostic indices based on clinical and immunohistochemical markers.
  • Adrenocortical carcinoma is a rare condition with an unpredictable prognosis as a rule.
  • Y = 1 when chronological age (CA) >33 mo, Y = 0 when CA < or =33 mo; L = 1 for right sided tumor and L = 0 for left sided tumor; H = 1 in presence of hypertension and H = 0 for normal blood pressure; T = length of disease in months; W = weight of tumor (g); O = 1 in the absence of p53 protein and O = 0 in the presence of p53.
  • [MeSH-major] Adrenal Cortex Neoplasms / physiopathology. Adrenocortical Carcinoma / physiopathology. Biomarkers, Tumor / metabolism. Models, Biological

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844468.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Siriwong S, Shuangshoti S, Saritsiri S, Pak-art P, Khovidhunkit W, Snabboon T: Functioning adrenocortical carcinoma with superior vena cava and upper airway obstructions. J Med Assoc Thai; 2006 Sep;89(9):1511-5
MedlinePlus Health Information. consumer health - Choking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functioning adrenocortical carcinoma with superior vena cava and upper airway obstructions.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is one of the most aggressive endocrine malignancies with a dismal prognosis.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Airway Obstruction / pathology. Vena Cava, Superior / pathology
  • [MeSH-minor] Adult. Cushing Syndrome / diagnosis. Fatal Outcome. Humans. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100393.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


38. Ohwada S, Izumi M, Tanahashi Y, Kawate S, Hamada K, Tsutsumi H, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Combined liver and inferior vena cava resection for adrenocortical carcinoma. Surg Today; 2007;37(4):291-7
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined liver and inferior vena cava resection for adrenocortical carcinoma.
  • PURPOSE: Adrenocortical carcinoma (ACC) is a rare malignancy, usually diagnosed at an advanced stage when it has invaded or adhered to adjacent organs.
  • RESULTS: Perioperative mortality was zero, and morbidity was 33.3%, with temporary liver failure in two patients and renal failure in one patient.
  • The 5-year disease-free survival rate was 16.7%.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / secondary. Adrenocortical Carcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Vena Cava, Inferior / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387560.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


39. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: a single institution experience. Am Surg; 2005 Jan;71(1):90-4
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: a single institution experience.
  • Adrenocortical carcinoma (ADCC) ranks among the least common malignant endocrine tumors.
  • Medical records of patients with the diagnosis of ADCC between 1990 and 2000 were reviewed.
  • Factors associated with a worse prognosis were stage of disease, nonoperative management, positive surgical margins, vascular invasion, and older age.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757066.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Hermsen IG, Groenen YE, Dercksen MW, Theuws J, Haak HR: Response to radiation therapy in adrenocortical carcinoma. J Endocrinol Invest; 2010 Nov;33(10):712-4
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to radiation therapy in adrenocortical carcinoma.
  • INTRODUCTION: Adrenocortical carcinoma (ACC) is a rare disease which is considered resistant to many treatments.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiotherapy. Adrenocortical Carcinoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20220294.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


41. Miller BS, Gauger PG, Hammer GD, Giordano TJ, Doherty GM: Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg; 2010 Sep;395(7):955-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade.
  • PURPOSE: Various staging systems for adrenocortical carcinoma (ACC) have been proposed.
  • We hypothesized that incorporating tumor grade into the current European Network for the Study of Adrenal Tumors (ENSAT) staging system would improve the ability to more accurately predict time to recurrence and death.
  • High-grade tumors are associated with shorter disease-free intervals and shorter overall survival.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694732.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E: Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer; 2010 Sep;17(3):797-807
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
  • To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane- and cisplatinum-based chemotherapy as first-line.
  • In the univariate analysis, resection of the primary, time since diagnosis, mitotane monotherapy as single first-line treatment, number of affected organs, plasma mitotane above 14 mg/l, and objective response were predictors of survival.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592067.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 78E4J5IB5J / Mitotane; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


43. Ding L, Murphy MB, He Y, Xu Y, Yeung LW, Wang J, Zhou B, Lam PK, Wu RS, Giesy JP: Effects of brominated flame retardants and brominated dioxins on steroidogenesis in H295R human adrenocortical carcinoma cell line. Environ Toxicol Chem; 2007 Apr;26(4):764-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of brominated flame retardants and brominated dioxins on steroidogenesis in H295R human adrenocortical carcinoma cell line.
  • In this study, an in vitro assay based on the H295R human adrenocortical carcinoma cell line, which possesses most key genes or enzymes involved in steroidogenesis, was used to examine the effects of five bromophenols, two polybrominated biphenyls (PBBs 77 and 169), 2,3,7,8-tetrabromodibenzo-p-dioxin, and 2,3,7,8-tetrabromodibenzofuran on the expression of 10 key steroidogenic genes.
  • Cell viability was not affected at the doses tested.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447562.001).
  • [ISSN] 0730-7268
  • [Journal-full-title] Environmental toxicology and chemistry
  • [ISO-abbreviation] Environ. Toxicol. Chem.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Complementary; 0 / Dioxins; 0 / Flame Retardants; 0 / Hydrocarbons, Brominated; 0 / Phosphoproteins; 0 / Steroids; 0 / steroidogenic acute regulatory protein; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.1.- / 17-Hydroxysteroid Dehydrogenases; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases
  •  go-up   go-down


44. Shen XC, Gu CX, Qiu YQ, Du CJ, Fu YB, Wu JJ: Estrogen receptor expression in adrenocortical carcinoma. J Zhejiang Univ Sci B; 2009 Jan;10(1):1-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor expression in adrenocortical carcinoma.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare but highly malignant tumor, and its diagnosis is mostly delayed and prognosis is poor.
  • RESULTS: At the time of diagnosis, 4 tumors were classified as Stage I, 4 as Stage II, 3 as Stage III, and 6 as Stage IV.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / metabolism. Adrenocortical Carcinoma / mortality. Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Curr Urol Rep. 2004 Feb;5(1):65-72 [14733841.001]
  • [Cites] J Urol. 1978 Dec;120(6):660-5 [731800.001]
  • [Cites] Cancer Res. 1983 Aug;43(8):3583-5 [6861130.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Endocr Rev. 1987 Feb;8(1):29-43 [3549276.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1882-4 [2924327.001]
  • [Cites] Am J Clin Pathol. 1992 Jan;97(1):73-83 [1728867.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):791-805 [9735134.001]
  • [Cites] World J Urol. 1999 Feb;17(1):26-34 [10096148.001]
  • [Cites] Ann R Coll Surg Engl. 1958 Sep;23(3):155-86 [13571886.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • (PMID = 19198016.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC2613956
  •  go-up   go-down


45. Pacella CM, Stasi R, Bizzarri G, Pacella S, Graziano FM, Guglielmi R, Papini E: Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma. Eur J Radiol; 2008 Apr;66(1):88-94
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma.
  • PURPOSE: To evaluate the feasibility, safety, and clinical benefits of percutaneous laser ablation (PLA) in patients with unresectable primary and metastatic adrenocortical carcinoma (ACC).
  • After a median follow-up after PLA of 27.0 months (range, 9-48 months), two patients have died of tumor progression, while two other patients remain alive and free of disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Laser Therapy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Combined Modality Therapy. Disease Progression. Feasibility Studies. Female. Humans. Male. Middle Aged. Mitotane / therapeutic use. Palliative Care. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498906.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


46. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B, Fassnacht M: Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab; 2008 Jun;93(6):2057-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
  • CONTEXT: Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis.
  • In advanced disease, mitotane given as monotherapy or combined either with etoposide, doxorubicin, and cisplatin or with streptozotocin is the recommended first-line therapy.
  • However, many patients have progressive disease despite treatment with these regimens.
  • Only one in 10 patients experienced a minor response (progression-free survival 8 months), whereas eight patients had progressive disease at the first staging.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Quinazolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Administration Routes. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Endocrinol Metab. 2008 Aug;93(8):3230. Ritte, Christian [corrected to Ritter, Christian]
  • (PMID = 18334586.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


47. Ohwada S, Izumi M, Kawate S, Hamada K, Toya H, Togo N, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol; 2007 Feb;37(2):108-13
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of stage III and IV adrenocortical carcinoma.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor usually diagnosed at an advanced stage on invasion of or adherence to adjacent organs.
  • The estimated 3-year disease-free and overall survivals for stage III were 20% and 40%, respectively, with a median follow-up of 32 months (range, 11-58).
  • The mean disease-free survival was 21.0 +/- 9.0 months (95% CI: 3.3-38.7).
  • The 3-year disease-free and overall survivals for stage III and IV were 14.3% and 28.6%, respectively.
  • The mean disease-free survival time was 18.6 +/- 6.7 months (95% CI: 5.4-31.8).
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277000.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


48. Fassnacht M, Allolio B: What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol (Oxf); 2010 Nov;73(5):561-5
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
  • In suspected nonmetastatic adrenocortical carcinoma (ACC) a careful preoperative diagnostic work up is needed including comprehensive endocrine analysis as recommended by the European Network for the Study of Adrenal Tumors (http://www.ENSAT.org/ACC.htm).
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20738315.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 78E4J5IB5J / Mitotane
  •  go-up   go-down


49. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C: Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer; 2008 Dec 1;113(11):3130-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor with a relatively poor prognosis.
  • METHODS: Patients diagnosed with ACC from 1985 to 2005 were identified from the National Cancer Data Base (NCDB).
  • Median age at diagnosis was 55 years.
  • CONCLUSIONS: ACC carries a poor prognosis for patients commonly presenting with large, locally invasive tumors, involved margins, and metastatic disease.
  • Survival is not affected by size but is diminished with increasing age, poorly differentiated tumors, involved margins, and the presence of regional and distant disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Registries. Survival Analysis. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • (PMID = 18973179.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M, German Adrenocortical Carcinoma Registry Group: Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol; 2010 Oct;58(4):609-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.
  • BACKGROUND: The role of laparoscopic adrenalectomy in the treatment of patients with adrenocortical carcinoma (ACC) is controversial.
  • OBJECTIVE: Our aim was to compare oncologic outcome in patients with ACC who underwent either open adrenalectomy (OA) or laparoscopic adrenalectomy (LA) for localised disease.
  • INTERVENTION: Patients were stratified into two groups according to the surgical procedure (LA or OA).
  • For comparison, we used both a matched pairs approach by selecting for each patient from the LA group (n=35) one corresponding patient from the OA group (n=117) and multivariate analysis in all 152 patients.
  • MEASUREMENTS: Disease-specific survival was chosen as the predefined primary end point.
  • Secondary end points were recurrence-free survival, frequency of tumour capsule violation and postoperative peritoneal carcinomatosis, and incidence and reasons for conversion from LA to OA.
  • RESULTS AND LIMITATIONS: LA and OA did not differ with regard to the primary end point using either the matched pairs approach (hazard ratio [HR] for death: 0.79; 95% confidence interval [CI], 0.36-1.72; p=0.55) or multivariate analysis (HR for death: 0.98; 95% CI, 0.51-1.92; p=0.92).
  • Similarly, adjusted recurrence-free survival was not different between LA and OA (HR: 0.91; 95% CI, 0.56-1.47; p=0.69).
  • In 12 of 35 patients of the LA group, surgery was converted to open surgery with no impact on the clinical outcome.
  • CONCLUSIONS: For localised ACC with a diameter of < or =10 cm, LA by an experienced surgeon is not inferior to OA with regard to oncologic outcome.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Laparoscopy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Dec;58(6):e53; author reply e54 [20864252.001]
  • (PMID = 20580485.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


51. Kasperlik-Zaluska AA, Zgliczynski W, Slapa RZ, Cichocki A: Retroperitoneal hemorrhage from adrenocortical carcinoma as a poor prognostic factor. Int J Biomed Sci; 2008 Mar;4(1):78-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal hemorrhage from adrenocortical carcinoma as a poor prognostic factor.
  • In most patients, adrenocortical carcinoma is diagnosed at an advanced stage of the disease.
  • A sudden retroperitoneal hemorrhage may sometimes be the first symptom of the adrenal cancer.
  • We describe four patients with adrenocortical carcinoma diagnosed during a retroperitoneal hemorrhage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23675071.001).
  • [ISSN] 1550-9702
  • [Journal-full-title] International journal of biomedical science : IJBS
  • [ISO-abbreviation] Int J Biomed Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3614665
  • [Keywords] NOTNLM ; adrenal cancer / retroperitoneal hemorrhage / steroids
  •  go-up   go-down


52. Abiven-Lepage G, Coste J, Tissier F, Groussin L, Billaud L, Dousset B, Goffinet F, Bertagna X, Bertherat J, Raffin-Sanson ML: Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis. Eur J Endocrinol; 2010 Nov;163(5):793-800
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare, severe disease.
  • For the survival analysis, pregnant patients were compared with a subgroup of nonpregnant women matched for age, stage, and year of diagnosis (1 pregnant patient/2 controls).
  • RESULTS: Adrenocortical tumors diagnosed during pregnancy or in the postpartum period tend to be more often cortisol-secreting tumors (P=0.06) and to be discovered at a more advanced stage than those in nonpregnant women, although the differences were not significant.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20699382.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A: Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg; 2006 May;30(5):872-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
  • BACKGROUND: Adrenocortical carcinoma (ACC), a rare and aggressive malignancy, accounts for up to 14% of adrenal incidentalomas.
  • The only chance of cure for ACC is diagnosis at an early stage; therefore, a main indication for adrenalectomy in patients with adrenal incidentaloma has been the potential risk of ACC.
  • Recent studies suggest that this has led to earlier stage of ACC at diagnosis, more curative operations, and better survival.
  • METHODS: We analyzed data on ACC from The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database.
  • Between the time quartiles compared (as well as annually), there was no significant difference at presentation in age at diagnosis, sex, race/ethnicity, tumor size, tumor grade, the frequency of distant metastasis, and overall TNM stage.
  • CONCLUSIONS: Although adrenal incidentalomas have become a common indication for adrenalectomy, this has not resulted in patients with ACC being diagnosed earlier or treated at a lower stage of disease at the national level.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy. Adrenocortical Carcinoma / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680602.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Koschker AC, Fassnacht M, Hahner S, Weismann D, Allolio B: Adrenocortical carcinoma -- improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes; 2006 Feb;114(2):45-51
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma -- improving patient care by establishing new structures.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and highly malignant tumour with a poor prognosis.
  • DIAGNOSIS: In case of an adrenal mass, hormonal workup before surgery is required for differential diagnosis, perioperative management, and for follow-up.
  • GANIMED, as a Germany-wide network of experts on adrenal diseases, has been founded allowing for improved gathering of data and joint studies.
  • ENSAT (European Network for the Study of Adrenal Tumours) has been brought to life, aiming at European standards for therapy, diagnosis and tumour banking.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / surgery
  • [MeSH-minor] Adrenalectomy. Clinical Trials as Topic. Diagnosis, Differential. Humans. Mutation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570232.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 24
  •  go-up   go-down


55. Ide H, Terado Y, Tokiwa S, Nishio K, Saito K, Isotani S, Kamiyama Y, Muto S, Imamura T, Horie S: Novel germ line mutation p53-P177R in adult adrenocortical carcinoma producing neuron-specific enolase as a possible marker. Jpn J Clin Oncol; 2010 Aug;40(8):815-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel germ line mutation p53-P177R in adult adrenocortical carcinoma producing neuron-specific enolase as a possible marker.
  • Adrenocortical cancer (ACC) is a rare and aggressive endocrine tumor.
  • Removal of the adrenocortical tumor with part of the transverse colon and tail of the pancreas, spleen and kidney was successfully performed following chemotherapy.
  • Immunohistochemical studies showed that the cancer cells were positive for NSE and overexpression of p53.
  • The genetic and biochemical data presented in this case confirm the importance of screening for p53 status in ACC with inherited cancer syndrome.
  • [MeSH-major] Adrenal Gland Neoplasms / enzymology. Adrenal Gland Neoplasms / genetics. Adrenocortical Carcinoma / enzymology. Adrenocortical Carcinoma / genetics. Biomarkers, Tumor / blood. Genes, p53 / genetics. Germ-Line Mutation. Phosphopyruvate Hydratase / blood

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421238.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


56. Letcher RJ, Sanderson JT, Bokkers A, Giesy JP, van den Berg M: Effects of bisphenol A-related diphenylalkanes on vitellogenin production in male carp (Cyprinus carpio) hepatocytes and aromatase (CYP19) activity in human H295R adrenocortical carcinoma cells. Toxicol Appl Pharmacol; 2005 Dec 1;209(2):95-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of bisphenol A-related diphenylalkanes on vitellogenin production in male carp (Cyprinus carpio) hepatocytes and aromatase (CYP19) activity in human H295R adrenocortical carcinoma cells.
  • The present study investigated the effects of the known xenoestrogen bisphenol A (BPA) relative to eight BPA-related diphenylalkanes on estrogen receptor (ER)-mediated vitellogenin (vtg) production in hepatocytes from male carp (Cyprinus carpio), and on aromatase (CYP19) activity in the human adrenocortical H295R carcinoma cell line.
  • [MeSH-minor] Adrenocortical Carcinoma / enzymology. Animals. Aromatase / metabolism. Benzhydryl Compounds. Biphenyl Compounds / pharmacology. Biphenyl Compounds / toxicity. Cell Line, Tumor. Cytochrome P-450 CYP1A1 / antagonists & inhibitors. Cytochrome P-450 CYP1A1 / metabolism. Estradiol / metabolism. Estrogen Receptor Modulators / pharmacology. Estrogen Receptor Modulators / toxicity. Humans. Inhibitory Concentration 50. Male. Receptors, Aryl Hydrocarbon / metabolism. Receptors, Estrogen / antagonists & inhibitors. Receptors, Estrogen / metabolism. Tamoxifen / pharmacology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907334.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkanes; 0 / Aromatase Inhibitors; 0 / Benzhydryl Compounds; 0 / Biphenyl Compounds; 0 / Estrogen Receptor Modulators; 0 / Estrogens, Non-Steroidal; 0 / Phenols; 0 / Receptors, Aryl Hydrocarbon; 0 / Receptors, Estrogen; 0 / Vitellogenins; 094ZI81Y45 / Tamoxifen; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Aromatase; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; MLT3645I99 / bisphenol A
  •  go-up   go-down


57. Hamanaka W, Yoneda S, Shirakusa T, Shirahama H, Tashiro Y, Iwasaki A, Shiraishi T, Tsuru H: Alpha-fetoprotein (AFP)-producing adrenocortical carcinoma--long survival with various therapeutic strategies including a lung resection: report of a case. Surg Today; 2008;38(3):275-8
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein (AFP)-producing adrenocortical carcinoma--long survival with various therapeutic strategies including a lung resection: report of a case.
  • Instead of a large metastatic lung tumor with hemothorax and the existence of metastases in other organs, combined therapy of repeated resections for metastases and adjuvant therapy allowed for almost a 36-month survival following the first recurrence and a good quality of life.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / metabolism. Adrenocortical Carcinoma / mortality. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307006.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


58. Lecka A, Ginalska-Malinowska M: [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006;12(3):234-6
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
  • [Transliterated title] Prawidłowa steroidogeneza po wieloletniej terapii mitotanem u pacjentki po leczeniu chirurgicznym raka kory nadnercza.
  • The main method of treatment of adrenocortical tumours is surgery.
  • Moreover, patients receiving mitotane should be carefully monitored for adrenal insufficiency and usually require long-term hormone replacement therapy.
  • We present a rare case of normalisation of the contralateral adrenal function after long-term mitotane therapy as a post-surgical treatment of the adrenocortical tumour.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Glands / physiopathology. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020662.001).
  • [ISSN] 1234-625X
  • [Journal-full-title] Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologów Dziecięcych
  • [ISO-abbreviation] Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Steroids; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


59. Fernandez-Ranvier GG, Weng J, Yeh RF, Shibru D, Khafnashar E, Chung KW, Hwang J, Duh QY, Clark OH, Kebebew E: Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J Surg; 2008 May;32(5):873-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13.
  • BACKGROUND: The most common genetic change observed in adrenocortical carcinoma is loss of heterozygozity on chromosome 11q13.
  • As genes on this chromosome may be important in the pathogenesis of adrenocortical carcinoma, we compared their expression profile between benign and malignant adrenocortical tissue.
  • METHODS: We used the Affymetrix GeneChip (U133 plus 2.0) array in 54 adrenocortical tumors (11 carcinoma and 43 benign).
  • The area under the receiver operating characteristic (ROC) curve (AUC) was used to determined the diagnostic accuracy of the differently expressed genes for distinguishing benign from malignant tumors.
  • RESULTS: We found 25 of the 314 genes on chromosome 11q13 to be differentially expressed between adrenocortical carcinoma and benign adrenocortical tumor.
  • All 25 were downregulated in adrenocortical carcinoma by 2-fold to 4.8-fold; 21 were validated to be differentially expressed by RT-PCR (Pearson's coefficient>0.5).
  • Six genes (SERPING1, MRPL48, TM7SF2, DDB1, NDUSF8, PRDX5) validated by RT-PCR were significantly differentially expressed between benign and malignant adrenocortical tumors (p<0.05) with an overall accuracy of 89% for SERPING1, 91% for MRPL48, 87% for TM7SF2, 88% for DDB1, 91% for NDUFS8, and 89% for PRDX5.
  • CONCLUSIONS: We have identified 25 genes located on chromosome 11q13 that are downregulated in adrenocortical carcinoma and may be candidate tumor suppressor genes.
  • Six of these genes were good diagnostic markers for distinguishing adrenocortical carcinoma from adenoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Chromosomes, Human, Pair 11 / genetics. Genes, Tumor Suppressor / physiology. Loss of Heterozygosity / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324346.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


60. Marshall DT, Gilbert JD, Byard RW: Adrenocortical carcinoma and sudden death. Forensic Sci Med Pathol; 2007 Mar;3(1):53-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma and sudden death.
  • A 26-year-old man who presented with a 2-year history of intermittent gynecomastia with recent onset of fever, night sweats, and abdominal distension was found to have a left-sided adrenocortical carcinoma with metastases to the liver and spine.
  • The thromboemboli had arisen from a tongue of tumor that had grown through the left adrenal vein into the inferior vena cava.
  • Despite a high rate of angio-invasion there are very few reports of sudden death resulting from this phenomenon in patients with adrenocortical carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25868890.001).
  • [ISSN] 1547-769X
  • [Journal-full-title] Forensic science, medicine, and pathology
  • [ISO-abbreviation] Forensic Sci Med Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Martarelli D, Pompei P, Baldi C, Mazzoni G: Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol; 2008 Apr;61(5):809-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice.
  • Adrenocortical carcinoma is a rare tumor of the adrenal gland which requires new therapeutic approaches as its early diagnosis is difficult and prognosis poor despite therapies used.
  • The aim of our study was to evaluate whether mebendazole may result therapeutically useful in the treatment of human adrenocortical carcinoma.
  • We analyzed the effect of mebendazole on human adrenocortical carcinoma cells in vitro and after implantation in nude mice.
  • Mebendazole significantly inhibited cancer cells growth, both in vitro and in vivo, the effects being due to the induction of apoptosis.
  • Moreover, mebendazole inhibited invasion and migration of cancer cells in vitro, and metastases formation in vivo.
  • Overall, these data suggest that treatment with mebendazole, also in combination with standard therapies, could provide a new protocol for the inhibition of adrenocortical carcinoma growth.
  • [MeSH-major] Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Mebendazole / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Humans. In Vitro Techniques. Male. Mice. Mice, Nude. Neoplasm Metastasis / prevention & control. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. MEBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581752.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 81G6I5V05I / Mebendazole
  •  go-up   go-down


62. Sasano H, Suzuki T, Moriya T: Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol; 2006;17(4):345-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma.
  • Discerning malignancy in resected adrenocortical neoplasms can pose diagnostic difficulty.
  • Macroscopic examination is the first important step toward diagnosis and should include accurate measurement of weight and dimension of the specimens and description of the cut surface of the tumors.
  • It is also important to sample the specimens for histological diagnosis near foci of hemorrhage and/or necrosis.
  • Histological scoring systems evaluating multiple parameters, especially the criteria of Weiss, have been shown to be reliable in differential diagnosis between adrenocortical adenoma and carcinoma.
  • A tumor is defined as adrenocortical carcinoma when three or more of the following criteria are met;.
  • The criteria are relatively straightforward and considered the most effective standard for diagnosis of adrenocortical malignancy.
  • However, great care should be taken in applying the criteria to histological evaluation of two relatively rare and peculiar adrenocortical tumors, adrenocortical oncocytoma and pediatric adrenocortical neoplasms.
  • At this juncture, ancillary biological or molecular markers are of little practical value in terms of differential diagnosis between adrenocortical adenoma and carcinoma but tumors with MIB1 or Ki-67 labeling index more than 2.5 may be considered malignant.
  • Prognostic markers of adrenocortical carcinoma have not been established other than complete respectability of the tumor.
  • It sometimes is important for surgical pathologists to differentiate adrenocortical carcinoma from metastatic malignancies of other sites.
  • An immunohistochemical evaluation of adrenal 4 binding protein (Ad4BP) or SF-1, a transcription factor of all steroidogenesis, can aid in this differential diagnosis because nuclear immunoreactivity for this transcription factor is relatively specific to steroid producing cells.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Adrenocortical Adenoma / diagnosis. Biomarkers, Tumor / analysis. Cell Count. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Ki-67 Antigen / analysis. Mitotic Index. Ubiquitin-Protein Ligases / analysis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525483.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Number-of-references] 33
  •  go-up   go-down


63. McDougal WS: Ruptured adrenocortical carcinoma as a cause of paediatric acute abdomen. J Urol; 2005 Mar;173(3):984

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ruptured adrenocortical carcinoma as a cause of paediatric acute abdomen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Surg Int. 2002 Dec;18(8):730-2 [12598975.001]
  • (PMID = 15711359.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Ramos-De la Medina A, Que FG: Adrenocortical carcinoma presenting as a retroperitoneal abscess: an unusual presentation of a rare tumor. Endocr Pract; 2007 Sep;13(5):567-70
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma presenting as a retroperitoneal abscess: an unusual presentation of a rare tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiography. Retropharyngeal Abscess / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Diagnosis, Differential. Fatal Outcome. Hormones / urine. Humans. Lung Neoplasms / diagnosis. Male. Middle Aged

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17872359.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


65. Suresh B, Kishore TA, Albert AS, Joy A: Myxoid adrenal cortical carcinoma--a rare variant of adrenocortical carcinoma. Indian J Med Sci; 2005 Nov;59(11):505-7
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid adrenal cortical carcinoma--a rare variant of adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340152.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


66. Khan S, Imtiaz KE: Adrenocortical carcinoma: a diagnostic and treatment dilemma. Br J Hosp Med (Lond); 2009 Jan;70(1):46-7
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: a diagnostic and treatment dilemma.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Seeding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357579.001).
  • [ISSN] 1750-8460
  • [Journal-full-title] British journal of hospital medicine (London, England : 2005)
  • [ISO-abbreviation] Br J Hosp Med (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Tan HS, Thai AC, Nga ME, Mukherjee JJ: Development of ipsilateral adrenocortical carcinoma sixteen years after resection of an adrenal tumour causing Cushing's syndrome. Ann Acad Med Singapore; 2005 Apr;34(3):271-4
MedlinePlus Health Information. consumer health - Cushing's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of ipsilateral adrenocortical carcinoma sixteen years after resection of an adrenal tumour causing Cushing's syndrome.
  • INTRODUCTION: At times, it may be difficult to differentiate early stage, low-grade adrenocortical carcinoma from benign adrenal adenoma.
  • CLINICAL PICTURE: A 53-year-old lady underwent right adrenalectomy for a 4-cm adrenocortical tumour causing Cushing's syndrome.
  • Histology revealed an adrenocortical adenoma.
  • Sixteen years later, she presented with a 14-cm adrenal tumour, again on the right side.
  • Histology confirmed adrenocortical carcinoma.
  • OUTCOME: She died of metastatic disease 17 months later.
  • CONCLUSIONS: This case highlights the importance of long-term, systematic follow-up of patients treated for benign adrenal adenomas, especially if the tumour size exceeds 4 cm.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Cushing Syndrome / etiology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adrenocortical Adenoma / pathology. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902349.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


68. Mwandila M, Waller H, Stott V, Mercer P: A case of a testosterone-secreting oncocytic adrenocortical carcinoma. N Z Med J; 2010 Nov 5;123(1325):80-2
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a testosterone-secreting oncocytic adrenocortical carcinoma.
  • Oncocytic neoplasms are most rarely found in the adrenal gland.
  • We present a case of a testosterone-secreting oncocytic adrenocortical carcinoma in a 19-year-old female who presented with acne, hirsutism and irregular menses.
  • Clinical investigations revealed an elevated testosterone and DHEA-S and a 4×5 cm left adrenal mass.
  • The histology showed the tumour to be comprised of oncocytic cells with granular, eosinophilic cytoplasm, features consistent with an oncocytic carcinoma.
  • This is the first case presented of a testosterone-secreting oncocytic adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / secretion. Adrenocortical Carcinoma / secretion. Testosterone / secretion
  • [MeSH-minor] Adrenalectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparoscopy. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21317966.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


69. Peppa M, Pikounis V, Papaxoinis G, Macheras A, Economopoulos T, Raptis SA, Hadjidakis D: Adrenocortical carcinoma secreting cortisol, androgens and aldosterone: a case report. Cases J; 2009;2:8951

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma secreting cortisol, androgens and aldosterone: a case report.
  • INTRODUCTION: Adrenocortical carcinoma is a rare malignancy with a poor prognosis and presents with mass effects and less often with signs of hormone excess (approximately 60% of all adrenocortical carcinoma's).
  • Hormonally active adrenocortical carcinomas most commonly secrete cortisol while the co-secretion of multiple steroid hormones is rare.
  • CASE PRESENTATION: We report the case of a 59 year-old woman with a medical history of hyperaldosteronism due to a right adrenal adenoma.
  • During follow up, she showed symptoms of hypercortisolism and hyperandrogenemia and a rapid growth of the adrenal mass.
  • She underwent right adrenalectomy and the histology revealed the presence of an adrenocortical carcinoma.
  • Six months post-operatively being on treatment with mitotane, she was diagnosed of metastatic disease to the liver.
  • CONCLUSION: The hormonal status should be carefully investigated in all cases of suspected adrenocortical carcinoma, as the pattern of hormone secretion may be a clue to the malignancy of an adrenal lesion.
  • In addition, more data are needed to clarify the clinical and prognostic significance of the combined production of all adrenocortical hormones affecting either the survival or the quality of life of adrenocortical carcinoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2650-5 [16670169.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Surgery. 2002 Dec;132(6):1008-11; discussion 1012 [12490848.001]
  • (PMID = 20181215.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827070
  •  go-up   go-down


70. Fareau GG, Vassilopoulou-Sellin R: Diagnostic challenges in adrenocortical carcinoma: recommendations for surveillance after surgical resection of selected adrenal nodules. Endocr Pract; 2007 Oct;13(6):636-41
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic challenges in adrenocortical carcinoma: recommendations for surveillance after surgical resection of selected adrenal nodules.
  • OBJECTIVE: To discuss challenges in the diagnosis of adrenocortical carcinoma and to suggest surveillance measures after removal of selected adrenal nodules.
  • METHODS: We present the case of a 65-year-old man with worsening hypertension and new-onset hypokalemia attributed to primary hyperaldosteronism due to a 3-cm right adrenal nodule.
  • RESULTS: A laparoscopic right adrenalectomy was performed, and the histologic diagnosis was a benign adenoma.
  • Magnetic resonance imaging showed an 8-cm mass in the right adrenal bed and multiple hepatic metastatic lesions.
  • Fine-needle biopsy confirmed the presence of adrenocortical carcinoma.
  • CONCLUSION: Despite a comprehensive biochemical, radiologic, and histologic assessment, the diagnosis of adrenocortical carcinoma can be missed.
  • We recommend that abdominal imaging be performed every 3 months for the first year and every 6 months for the second year after surgical removal of selected adrenal nodules.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenal Glands / surgery. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adrenalectomy. Adrenocortical Adenoma / complications. Adrenocortical Adenoma / diagnosis. Adrenocortical Adenoma / surgery. Aged. Humans. Hyperaldosteronism / complications. Hyperaldosteronism / pathology. Hypertension / etiology. Hypokalemia / etiology. Magnetic Resonance Imaging. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954420.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Fassnacht M, Allolio B: Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab; 2009 Apr;23(2):273-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical management of adrenocortical carcinoma.
  • Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy, and most of the diagnostic and therapeutic strategies are not fully established according to criteria of evidence-based medicine.
  • International Consensus Conference 2003 and networks like the European Network for the Study of Adrenal Tumours (ENSAT)) have significantly advanced the field.
  • In advanced disease not amenable to radical resection, cytotoxic drugs will be added to mitotane.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / metabolism. Adrenal Cortex Hormones / physiology. Animals. Disease Progression. Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500769.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 100
  •  go-up   go-down


72. Suh I, Guerrero MA, Kebebew E: Gene-expression profiling of adrenocortical carcinoma. Expert Rev Mol Diagn; 2009 May;9(4):343-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-expression profiling of adrenocortical carcinoma.
  • Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior.
  • The clinical management of ACC is complicated by the inadequacy of current diagnostic modalities to accurately distinguish benign from malignant adrenocortical tumors.
  • In addition, efforts to better predict clinical tumor behavior are limited by the lack of a better understanding of the molecular mechanisms of adrenocortical carcinogenesis.
  • Thus, there is a pressing need for the development of new therapeutic approaches for patients with ACC, as most patients present with advanced locoregional and metastatic disease.
  • Since 2003, several studies have reported distinct gene-expression profiles between benign and malignant adrenocortical tumors that may have diagnostic and prognostic clinical utility.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Gene Expression Profiling

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19441174.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 56
  •  go-up   go-down


73. Mezhir JJ, Song J, Piano G, Testa G, Raman J, Al-Ahmadie HA, Angelos P: Adrenocortical carcinoma invading the inferior vena cava: case report and literature review. Endocr Pract; 2008 Sep;14(6):721-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma invading the inferior vena cava: case report and literature review.
  • OBJECTIVE: To present the case of a man with a right-sided adrenocortical carcinoma that invaded the inferior vena cava and was managed by radical resection and vein patch repair.
  • The literature is reviewed for the management of adrenocortical carcinoma in conjunction with inferior vena cava invasion.
  • RESULTS: In a 34-year-old man with new-onset abdominal pain, abdominal imaging disclosed a large right adrenal mass with invasion into the inferior vena cava.
  • Laboratory values revealed that the adrenal mass was likely nonfunctional.
  • At surgical intervention with use of cardiopulmonary bypass, the mass was removed en bloc with the adrenal gland, right kidney, and the wall of the inferior vena cava, and the inferior vena cava was reconstructed with bovine pericardium.
  • Thus, this scenario should not preclude attempted curative resection in patients with adrenal cancer.
  • [MeSH-major] Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / pathology. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996792.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


74. Delaney HM, Prauner RD, Person DA: Germline p53 mutation in a Micronesian child with adrenocortical carcinoma and subsequent osteosarcoma. J Pediatr Hematol Oncol; 2008 Nov;30(11):803-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline p53 mutation in a Micronesian child with adrenocortical carcinoma and subsequent osteosarcoma.
  • In 1990, an 18-month-old Micronesian girl was initially diagnosed with a right adrenocortical carcinoma.
  • Given this child's remarkable history of malignancy, she underwent testing for a genetic mutation that is associated with increased cancer formation.
  • One such cancer syndrome is called Li-Fraumeni syndrome where approximately 70% of patients carry a genetic mutation in the p53 tumor suppressor gene.
  • Patients with LFS are at risk for developing cancers of the breast, soft tissues, brain, bone, adrenal gland, and blood cells.
  • Mutational analysis of our patient did reveal the presence of a germline mutation of the p53 tumor suppressor gene.
  • She was found to have a base pair change (A-->C) at nucleotide 394 resulting in a lysine to glutamine amino acid change at codon 132 (K132Q), which remarkably has never been described in association with either adrenocortical carcinoma or osteosarcoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Bone Neoplasms / genetics. Germ-Line Mutation / genetics. Neoplasms, Second Primary / genetics. Osteosarcoma / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989156.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


75. Assié G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M, Baudin E: Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab; 2007 Jan;92(1):148-54
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic parameters of metastatic adrenocortical carcinoma.
  • CONTEXT: Prognostic parameters of metastatic adrenocortical carcinoma (ACC) are poorly characterized.
  • CONCLUSION: Metastatic ACC is a heterogeneous disease with poor outcome.
  • [MeSH-major] Adrenal Cortex Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062775.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Bacchetta J, Droz JP: [Practical use of o,p'DDD in adrenocortical carcinoma]. Bull Cancer; 2005 Mar;92(3):273-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Practical use of o,p'DDD in adrenocortical carcinoma].
  • [Transliterated title] Thérapeutique pratique par l'o,p'DDD dans le carcinome corticosurrénalien.
  • Adrenocortical carcinoma (AC) is a rare tumor of poor prognosis.
  • Five patients (four with AC and one with a metastatic Leydig cell tumor of the testis) were treated by Lysodren.
  • Surgery is an important part of metastatic disease treatment.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820922.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


77. Lee JO, Lee KW, Kim CJ, Kim YJ, Lee HE, Kim H, Kim JH, Bang SM, Kim JS, Lee JS: Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol; 2009 Mar;39(3):183-5
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adrenocortical carcinoma treated with sunitinib: a case report.
  • Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis.
  • Palliative chemotherapy can be considered in patients with metastatic disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / pathology. Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Indoles / therapeutic use. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168875.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 78E4J5IB5J / Mitotane
  •  go-up   go-down


78. Sone M, Shibata H, Homma K, Tamura N, Akahira J, Hamada S, Yahata M, Fukui N, Itoh H, Sasano H, Nakao K: Close examination of steroidogenesis disorders in a DOC- and progesterone-producing adrenocortical carcinoma. Endocrine; 2009 Feb;35(1):25-33
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Close examination of steroidogenesis disorders in a DOC- and progesterone-producing adrenocortical carcinoma.
  • We report a case of hypertension, hypokalemia, and amenorrhea accompanying an adrenocortical carcinoma.
  • A 27-year-old woman was admitted to our hospital because of a left adrenal incidentaloma.
  • After the tumor was removed, levels of all adrenal steroids were normalized.
  • Based on the Weiss criteria, the tumor was diagnosed as an adrenocortical carcinoma, and immunohistochemical analysis of steroidogenic enzymes revealed disorganized steroidogenesis in the tumor tissue.
  • With adrenocortical carcinomas, heterogeneity of individual steroid producing enzymes within tumor cells can lead to hypersecretion of various steroid intermediates, even when steroid end products are within the normal range.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis. Desoxycorticosterone / metabolism. Endocrine System Diseases / etiology. Progesterone / metabolism
  • [MeSH-minor] Adult. Female. Humans. Hypertension / diagnosis. Incidental Findings. Models, Biological. Physical Examination. Steroids / biosynthesis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985457.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Steroids; 40GP35YQ49 / Desoxycorticosterone; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


79. Haleblian GE, Wilson C, Haddad D, Albala DM: Adrenocortical carcinoma: role of laparoscopic surgery in treatment. Expert Rev Anticancer Ther; 2007 Sep;7(9):1295-300
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: role of laparoscopic surgery in treatment.
  • Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis.
  • It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths.
  • Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical management, appropriate anesthesia and refined surgical techniques have come together to render the surgical management of adrenal abnormalities a safe endeavor with predictable outcomes.
  • While there is a general agreement on the suitability of the laparoscopic approach for benign adrenal lesions, controversy remains regarding the use of laparoscopy for suspected adrenal malignancies.
  • This paper provides an overview of adrenal cancer and reviews the literature on laparoscopic adrenalectomy for cancer, including the operative techniques, indications and contraindications.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Laparoscopy / methods

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892430.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 28
  •  go-up   go-down


80. Ali AE, Raphael SJ: Functional oncocytic adrenocortical carcinoma. Endocr Pathol; 2007;18(3):187-9
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional oncocytic adrenocortical carcinoma.
  • We present a case of oncocytic adrenocortical carcinoma in a 25-year-old man who presented with persistent hypertension, hypokalemia, and a large right adrenal mass.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / physiopathology. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / physiopathology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058268.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 13
  •  go-up   go-down


81. Kirschner LS: Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab; 2006 Jan;91(1):14-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging treatment strategies for adrenocortical carcinoma: a new hope.
  • CONTEXT: Adrenocortical carcinoma (ACC) is a rare cancer but one that has devastating consequences for affected patients.
  • Surgery is the mainstay of therapy, although the high frequency of metastatic disease implies that it is frequently noncurative.
  • Traditional cytotoxic chemotherapy for ACC has generally produced disappointing responses, implying the need for the new therapies for this disease.
  • EVIDENCE ACQUISITION: Review articles and primary literature were identified by extensive PubMed searching to obtain papers evaluating the current state of knowledge regarding ACC, as well as assessing the development of new therapeutic modalities for the treatment of cancer.
  • This review provides a brief summary of the progress and prospects of each of these modalities and focuses on emerging data and treatments that may alter the course of this disease within the next few years.
  • CONCLUSIONS: Despite the current grim outlook, the recent applications of emerging technology to the study of ACC and the development of newer, "targeted" therapies for cancer suggest the possibility of a new hope for patients with this disease, although these therapies will need to be evaluated by rigorous clinical trials to verify their effectiveness.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Carcinoma / therapy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234301.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 127
  •  go-up   go-down


82. Lawnicka H, Kowalewicz-Kulbat M, Sicinska P, Kazimierczuk Z, Grieb P, Stepien H: Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro. Cell Tissue Res; 2010 May;340(2):371-9
Hazardous Substances Data Bank. 17ALPHA-HYDROXYPROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro.
  • CK2 kinase (casein kinase-2) has been suggested to be a constituent of a neoplastic milleu, and its inhibition might represent a new approach to cancer therapy.
  • Adrenocortical carcinomas (ACCs) are highly malignant neoplasms with poor overall prognosis.
  • We have examined the effects of 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), a potent CK2 inhibitor, on the H295R human adrenocortical cancer cell line.
  • Cell growth as measured by the MTT and 5-bromo-2'-deoxyuridine incorporation assays is inhibited, and cell cycle analysis has revealed a slight induction of apoptosis.
  • [MeSH-major] Adrenal Cortex Hormones / secretion. Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Benzimidazoles / pharmacology. Casein Kinase II / antagonists & inhibitors. Cell Proliferation / drug effects. Protein Kinase Inhibitors / pharmacology
  • [MeSH-minor] 17-alpha-Hydroxyprogesterone / metabolism. Aldosterone / secretion. Antineoplastic Agents / pharmacology. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Dehydroepiandrosterone Sulfate / metabolism. Drug Screening Assays, Antitumor. Humans. Hydrocortisone / secretion

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20383646.001).
  • [ISSN] 1432-0878
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 4,5,6,7-tetrabromobenzimidazole; 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Protein Kinase Inhibitors; 4964P6T9RB / Aldosterone; 57B09Q7FJR / Dehydroepiandrosterone Sulfate; 68-96-2 / 17-alpha-Hydroxyprogesterone; EC 2.7.11.1 / Casein Kinase II; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


83. Song R, Duarte TL, Almeida GM, Farmer PB, Cooke MS, Zhang W, Sheng G, Fu J, Jones GD: Cytotoxicity and gene expression profiling of two hydroxylated polybrominated diphenyl ethers in human H295R adrenocortical carcinoma cells. Toxicol Lett; 2009 Feb 25;185(1):23-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity and gene expression profiling of two hydroxylated polybrominated diphenyl ethers in human H295R adrenocortical carcinoma cells.
  • Two hydroxylated PBDEs (OH-PBDEs), 2-OH-BDE47 and 2-OH-BDE85, were investigated for their effects on cell viability/proliferation, DNA damage, cell cycle distribution and gene expression profiling in H295R adrenocortical carcinoma cells.
  • We discuss whether OH-PBDE bioaccumulation could result in impairment of the adrenocortical secretory function.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Gene Expression Profiling. Halogenated Diphenyl Ethers / toxicity
  • [MeSH-minor] Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Endoplasmic Reticulum / drug effects. Humans

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095052.001).
  • [ISSN] 0378-4274
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Halogenated Diphenyl Ethers
  •  go-up   go-down


84. Hah JO: Intensive chemotherapy with autologous PBSCT for advanced adrenocortical carcinoma in a child. J Pediatr Hematol Oncol; 2008 Apr;30(4):332-4
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy with autologous PBSCT for advanced adrenocortical carcinoma in a child.
  • Adrenocortical carcinoma (ACC) is a rare tumor in children.
  • We report successful treatment of a 3-year-old girl with ACC and lung metastases.
  • Autologous peripheral blood stem-cell transplantation was performed after preconditioning with carboplatinum, etoposide, and melphalan.
  • She has been well for 2 years since the time of diagnosis.
  • Surgical resection of the primary and metastatic lesions with chemotherapy followed by autologous peripheral blood stem-cell transplantation could be an effective treatment for advanced ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Peripheral Blood Stem Cell Transplantation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391707.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Misić M, Vidas Z, Skegro D, Kocman B, Jelić-Puskarić B, Kardum-Skelin I: Fine needle aspiration cytology of adrenocortical carcinoma--case report. Coll Antropol; 2010 Jun;34(2):665-9
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of adrenocortical carcinoma--case report.
  • Ultrasonography (US) revealed a solitary tumor mass, eight cm in size, of the right adrenal gland.
  • Laboratory tests showed it to be a hormonally active, androgen secreting tumor (elevated testosterone level), which was consistent with the clinical picture of the disease.
  • After histopathological analysis tumor was signed out as adrenocortical carcinoma, a low risk carcinoma according to Weiss' classification.
  • The finding was verified by computerized tomography and the patient was reoperated on.
  • Cytologic opinion was recidive of primary malignant disease.
  • ACC is a rare malignant epithelial tumor of adrenal cortical cells, with high malignant potential.
  • Morphologically (histopathology and cytology), differential diagnosis includes adenoma on the one hand, and renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) on the other hand.
  • A combined evaluation of clinical features, size or weight, microscopic appearance, immunohistochemical and molecular genetic data is necessary to ensure a correct diagnosis.
  • The purpose of this case report is to present clinical and cytomorphologic features of our case of adrenocortical carcinoma which is very rare in cytology practice.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Carcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698150.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


86. Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, Allolio B, Terzolo M: Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol; 2010 Aug 10;28(23):e401-2; author reply e403
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2009 Sep 20;27(27):4619-29 [19667279.001]
  • (PMID = 20567001.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


87. White MA, Shockley K: Adrenocortical carcinoma with renal vein invasion in a woman with a horseshoe kidney. Urology; 2006 Nov;68(5):1119-20
Genetic Alliance. consumer health - Horseshoe kidney.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma with renal vein invasion in a woman with a horseshoe kidney.
  • [MeSH-major] Adrenal Cortex Neoplasms / complications. Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / complications. Adrenocortical Carcinoma / pathology. Kidney / abnormalities. Neoplastic Cells, Circulating. Renal Veins

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113906.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Andersen KF, Mellemgaard A, Hendel HW: Multimodality imaging in a patient with adrenocortical carcinoma leading to peptide receptor radionuclide therapy. Clin Nucl Med; 2009 Aug;34(8):543-8
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality imaging in a patient with adrenocortical carcinoma leading to peptide receptor radionuclide therapy.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / radiotherapy. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / radiotherapy. Diagnostic Imaging / methods. Receptors, Peptide / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617743.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Peptide; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


89. Wen MJ, Lin YF, Chen JS: Newly developed hypertension as an early marker of recurrence of adrenocortical carcinoma with high renin expression. Int J Urol; 2008 Jun;15(6):540-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newly developed hypertension as an early marker of recurrence of adrenocortical carcinoma with high renin expression.
  • Adrenocortical carcinoma can recur frequently after successful surgery but no adequate markers can detect this recurrence.
  • Here, we present a recurrence of adrenocortical carcinoma with a high renin expression, after successful surgery, where hypertension has developed again.
  • Based on our findings, follow-up blood pressure assessment may effectively predict the recurrence of adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / complications. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / complications. Adrenocortical Carcinoma / metabolism. Hypertension / etiology. Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / metabolism. Renin / biosynthesis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489644.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 3.4.23.15 / Renin
  •  go-up   go-down


90. Sun X, Ayala A, Castro CY: Adrenocortical carcinoma with concomitant myelolipoma in a patient with hyperaldosteronism. Arch Pathol Lab Med; 2005 Jun;129(6):e144-7
Genetic Alliance. consumer health - Hyperaldosteronism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma with concomitant myelolipoma in a patient with hyperaldosteronism.
  • We present a case of aldosterone-secreting adrenocortical carcinoma with concomitant myelolipoma.
  • Clinical workup revealed an increased serum aldosterone level, hypokalemia, and metabolic alkalosis, and a left adrenal mass was found on computed tomography.
  • Although rare, aldosterone-secreting carcinoma associated with myelolipoma should be included in the differential diagnosis of adrenal gland masses.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Hyperaldosteronism / pathology. Myelolipoma / pathology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913443.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 4964P6T9RB / Aldosterone
  •  go-up   go-down


91. Bussey KJ, Demeure MJ: Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment. Future Oncol; 2009 Jun;5(5):641-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.
  • Adrenocortical carcinoma (ACC) is an aggressive endocrine tumor with a poor 5-year survival rate of 10-20%.
  • Although ACC is extremely rare, recent advances in genomic and expression profiling, coupled with knowledge gained from the study of the inherited syndromes that increase ACC risk, are beginning to bring together a picture of a tumor type dependent on p53, the G2/M cell cycle transition and IGF2 stimulation.
  • Nevertheless, ACC remains a heterogeneous disease.
  • Advances in treatment will depend on exploiting those pathways already implicated in ACC, along with those yet to be identified, and testing those treatments in better models of the disease than the three cell lines that currently exist and are widely available to the community.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / genetics. Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / genetics. Adrenocortical Carcinoma / therapy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519204.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down


92. Mermejo LM, Elias Junior J, Saggioro FP, Tucci Junior S, Castro Md, Moreira AC, Elias PC: Giant adrenal myelolipoma associated with 21-hydroxylase deficiency: unusual association mimicking an androgen-secreting adrenocortical carcinoma. Arq Bras Endocrinol Metabol; 2010 Jun;54(4):419-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant adrenal myelolipoma associated with 21-hydroxylase deficiency: unusual association mimicking an androgen-secreting adrenocortical carcinoma.
  • The objective of this study was to describe a case of giant myelolipoma associated with undiagnosed congenital adrenal hyperplasia (CAH) due to 21-hydroxylase (21OH) deficiency.
  • Five seven year-old male patient referred with abdominal ultrasound revealing a left adrenal mass.
  • Biochemical investigation revealed hyperandrogenism and imaging exams characterized a large heterogeneous left adrenal mass with interweaving free fat tissue, compatible with the diagnosis of myelolipoma, and a 1.5 cm nodule in the right adrenal gland.
  • Biochemical correlation has brought concerns about differential diagnosis with adrenocortical carcinoma, and surgical excision of the left adrenal mass was indicated.
  • Further investigation resulted in the diagnosis of CAH due to 21OH deficiency.
  • Concluded that CAH has been shown to be associated with adrenocortical tumors.
  • Although rare, myelolipoma associated with CAH should be included in the differential diagnosis of adrenal gland masses.
  • Moreover, CAH should always be ruled out in incidentally detected adrenal masses to avoid unnecessary surgical procedures.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Hyperplasia, Congenital / diagnosis. Adrenocortical Carcinoma / diagnosis. Myelolipoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Steroid 21-Hydroxylase / genetics

  • Genetic Alliance. consumer health - 21-Hydroxylase Deficiency.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625655.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 1.14.99.10 / Steroid 21-Hydroxylase
  •  go-up   go-down


93. Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B, Fassnacht M: Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol; 2010 Feb;162(2):349-56
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.
  • OBJECTIVE: No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended mitotane as monotherapy or combined with etoposide, doxorubicin and cisplatin or with streptozotocin as first-line systemic therapy.
  • None of them experienced any objective response or stable disease.
  • Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903796.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Wängberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Odén A, Ahlman H: The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer; 2010 Mar;17(1):265-72
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
  • Adrenocortical carcinoma (ACC) is a rare tumour disease with sinister prognosis also after attempts to radical surgery; better prognosis is seen for low-stage tumours.
  • The disease-specific 5-year survival was high (64.1%); very high for patients with low-stage tumours without evident relation to mitotane levels.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / mortality. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / mortality. Adrenocortical Carcinoma / surgery. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026647.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


95. Ozimek A, Diebold J, Linke R, Heyn J, Hallfeldt K, Mussack T: Bilateral primary adrenal non-Hodgkin's lymphoma and primary adrenocortical carcinoma--review of the literature preoperative differentiation of adrenal tumors. Endocr J; 2008 Aug;55(4):625-38
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral primary adrenal non-Hodgkin's lymphoma and primary adrenocortical carcinoma--review of the literature preoperative differentiation of adrenal tumors.
  • Most of the adrenal tumors that are incidentally detected are benign adenomas.
  • The incidence of malignant adrenal tumors including adrenocortical carcinoma (ACC) and primary adrenal lymphoma (PAL) is rather low.
  • As many patients with ACC and PAL are diagnosed at an advanced stage of disease, the overall survival time of both entities remains poor.
  • Unfortunately hitherto preoperative diagnosis of potentially malignant adrenal masses is still a main problem in the treatment of adrenal tumors.
  • We present the case of a 57-year-old male patient with ACC and the case of an 87-year-old male patient with PAL and provide a systematic comparison of the clinical and pathological features of both entities.
  • In both cases clinical and radiological features resulted in an initially false diagnosis.
  • We propose some guidelines for diagnosis and surgical management of adrenal tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Gland Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490838.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 78E4J5IB5J / Mitotane
  • [Number-of-references] 55
  •  go-up   go-down


96. Barzon L, Masi G, Fincati K, Pacenti M, Pezzi V, Altavilla G, Fallo F, Palù G: Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma. Eur J Endocrinol; 2005 Nov;153(5):629-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma.
  • OBJECTIVE: Adrenocortical tumors may originate from the zona glomerulosa, zona fasciculata, or zona reticularis and be associated with syndromes due to overproduction of mineralocorticoids, glucocorticoids, or androgens respectively.
  • We report an unusual case of recurrent adrenocortical carcinoma (ACC), which seems to contradict the paradigm of functional adrenal zonation.
  • METHODS AND RESULTS: Extensive pathologic examination showed that this shift in steroid hormone production was paralleled by an attenuation of tumor cell atypia and polymorphism, whereas gene expression profile analysis demonstrated a change in expression of adrenal steroidogenic enzymes.
  • Moreover, cancer progression was associated with overexpression of the inhibin-alpha subunit, which could have contributed to the phenotypic changes.
  • CONCLUSIONS: This case of recurrent ACC demonstrates that adrenocortical cells can reverse their differentiation program during neoplastic progression and change their specific hormone synthesis, as a consequence of modifications in the expression profile of steroidogenic enzymes and cofactors.
  • These findings, besides opening new perspectives to study adrenocortical cell plasticity and potential, demonstrate how conventional clinical and pathologic evaluation can be combined with genomic analysis in order to dissect thoroughly the biology of cancer.


97. Patel VV, Shah DS, Raychaudhari CR, Patel KB: Giant non-functioning adrenocortical carcinoma: A rare childhood tumor. Indian J Med Paediatr Oncol; 2010 Apr;31(2):65-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant non-functioning adrenocortical carcinoma: A rare childhood tumor.
  • Adrenocortical carcinoma (ACC) is a rare malignancy, especially in children.
  • Empty left renal fossa and compensatory enlarged right kidney were seen.
  • With a stage IV disease, the patient died after 2 months from diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 1999 Jul-Aug;19(4):989-1008 [10464805.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):755-9 [11222220.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Pediatr Pathol Mol Med. 2003 Sep-Oct;22(5):405-10 [14692192.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 [9215267.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):108-13 [17277000.001]
  • [Cites] Neth J Med. 2007 Feb;65(2):55-60 [17379929.001]
  • [Cites] Oncology. 1988;45(1):15-7 [3340389.001]
  • [Cites] Jpn J Surg. 1985 Nov;15(6):477-82 [3831502.001]
  • [Cites] Jpn J Clin Oncol. 2009 Mar;39(3):183-5 [19168875.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • (PMID = 21209768.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970938
  • [Keywords] NOTNLM ; Adrenocortical carcinoma / adrenocortical tumor / nonfunctioning
  •  go-up   go-down


98. Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat SF, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI: External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU Int; 2009 Dec;104(11):1661-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma.
  • OBJECTIVE: To develop nomograms predicting cancer-specific and all-cause mortality in patients managed with either surgery or no surgery for adrenocortical carcinoma (ACC).
  • Nomograms based on Cox regression model-derived coefficients were used for predicting the cancer-specific and all-cause mortality, and were tested using area under the receiver operating characteristics (ROC) curve.
  • RESULTS: In cancer-specific analyses, the median survival of patients within the development cohort was 26 months, vs 71 months in the external validation cohort (P < 0.001).
  • Three variables (age, stage and surgical status) were included in the nomograms predicting cancer-specific and all-cause mortality.
  • In the external validation cohort, the nomograms achieved between 72 and 80% accuracy for prediction of cancer-specific or all-cause mortality at 1-5 years after either surgery or diagnosis of ACC for non-surgical patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / mortality. Nomograms

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493261.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


99. Aiba M, Fujibayashi M: Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol; 2005;16(1):13-22
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological diagnosis and prognostic factors in adrenocortical carcinoma.
  • A great majority of adrenocortical tumors are benign, and many adrenocortical carcinomas (ACC) are obviously malignant at presentation.
  • The histopathological diagnosis of ACC is occasionally difficult, particularly with stage I and stage II disease.
  • Histopathological prognostic factors of ACC have not been fully established because of the rarity of the disease.
  • These special type tumors include pediatric adrenocortical tumors, oncocytomas, and aldosterone-producing tumors of pure zona glomerulosa type.
  • Then we present three cases with unusual small adrenocortical tumors.
  • One patient had an unequivocal ACC showing metastatic disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic. Adult. Aged. Aged, 80 and over. Aldosterone / metabolism. Biomarkers, Tumor / metabolism. Cell Nucleus / pathology. Female. Humans. Immunohistochemistry. Infant. Insulin-Like Growth Factor II / metabolism. Male. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000842.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 4964P6T9RB / Aldosterone; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


100. Cantón RF, Sanderson JT, Letcher RJ, Bergman A, van den Berg M: Inhibition and induction of aromatase (CYP19) activity by brominated flame retardants in H295R human adrenocortical carcinoma cells. Toxicol Sci; 2005 Dec;88(2):447-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition and induction of aromatase (CYP19) activity by brominated flame retardants in H295R human adrenocortical carcinoma cells.
  • Our study assessed the potential effects of nineteen BDEs, five hydroxylated BDEs (OH-BDEs), one methoxylated BDE (CH(3)O-BDE), tetrabromobisphenol-A (TBBPA), its dibromopropane ether derivative (TBBPA-DBPE), and the brominated phenols/anisols 2,4,6-tribromophenol (TBP), 4-bromophenol (4BP) and 2,4,6-tribromoanisole (TBA) on the catalytic activity of the steroidogenic enzyme aromatase (CYP19) in H295R human adrenocortical carcinoma cells.
  • [MeSH-major] Adrenal Cortex Neoplasms / enzymology. Adrenocortical Carcinoma / enzymology. Aromatase / biosynthesis. Aromatase Inhibitors / toxicity. Environmental Pollutants / toxicity. Flame Retardants / toxicity. Polybrominated Biphenyls / toxicity
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Enzyme Induction. Humans

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177243.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Environmental Pollutants; 0 / Flame Retardants; 0 / Polybrominated Biphenyls; EC 1.14.14.1 / Aromatase
  •  go-up   go-down






Advertisement